



(11) **EP 3 351 261 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
25.07.2018 Bulletin 2018/30

(51) Int Cl.:
A61K 38/20 ^(2006.01) **A61K 39/395** ^(2006.01)
A61K 45/06 ^(2006.01) **A61P 35/00** ^(2006.01)

(21) Application number: **18160057.8**

(22) Date of filing: **10.10.2012**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **11.10.2011 EP 11184644**
10.11.2011 EP 11188625
19.09.2012 EP 12185108

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
12780684.2 / 2 766 035

(71) Applicant: **Universität Zürich**
8006 Zürich (CH)

(72) Inventors:
• **BECHER, Burkhard**
8124 Maur (CH)
• **VOM BERG, Johannes**
8051 Zürich (CH)

(74) Representative: **Schulz Junghans**
Patentanwälte PartGmbB
Großbeerenstraße 71
10963 Berlin (DE)

Remarks:

This application was filed on 05-03-2018 as a
divisional application to the application mentioned
under INID code 62.

(54) **COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF
T-CELL INHIBITORY MOLECULES FOR TUMOUR THERAPY**

(57) The invention relates to a combination medica-
ment for use in the therapy of a malignant neoplastic
disease, comprising an IL-12 polypeptide, or a nucleic
acid expression vector encoding said IL-12 polypeptide,
and a non-agonist ligand, particularly an antibody, capa-
ble of binding to one of PD-1, PD-L1 or PD-L2, with a

dissociation constant of at least 10^{-7} M⁻¹. The non-ago-
nist ligand is provided as a dosage form for systemic
delivery, and the IL-12 polypeptide, or said nucleic acid
expression vector, is provided by administration into a
tumour, into the vicinity of a tumour, or to the lymph node
associated with a tumour.

EP 3 351 261 A1

Description

[0001] The present invention relates to compositions and methods for treating cancer, in particular, to immunotherapy of malignant neoplastic disease such as glioma, by administering an effective dose of a polypeptide with IL-12 biological activity and a non-agonist ligand of a T-cell downregulator, particularly a non-agonist ligand to CTLA-4 and/or to Programmed Death 1 (PD-1).

[0002] Glioblastoma multiforme (GBM) is the most malignant astrocytic tumour. GBM exhibits an invasive and destructive growth pattern; it is the most common and most aggressive malignant primary brain tumour in humans, accounting for 20 % of all intracranial tumours. In most European countries and North America, GBM incidence is in the range of 3-3.5 new cases per 100'000 population per year. The clinical history of the disease is usually short (less than 3 months in more than 50% of cases) and patients diagnosed with GBM show a median survival of 14-18 months despite aggressive surgery, radiation, and chemotherapy. The ability of gliomas to withstand conventional treatment regimens is one of the greatest challenges of modern neuro-oncology.

[0003] Interleukin (IL)-12 is the prototype of a group of heterodimeric cytokines with predominantly inflammatory properties. IL-12 polarizes naive helper T-cells to adopt a TH1 phenotype and stimulates cytotoxic T and NK-cells. IL-12 binds to the IL-12 receptor (IL-12R), which is a heterodimeric receptor formed by IL-12R- β 1 and IL-12R- β 2. The receptor complex is primarily expressed by T cells, but also other lymphocyte subpopulations have been found to be responsive to IL-12.

[0004] The therapeutic application of IL-12 in various tumour entities has been suggested. Clinical trials in cancer patients, however, had to be halted since systemic application evoked serious adverse events at effective doses, including fatalities. While research in recent years has mainly focused on various administration routes of IL-12, there remain open questions on the exact mechanisms by which IL-12 exerts its tumour-suppressive properties.

[0005] CTLA-4 and PD-1 are both members of the extended CD28/CTLA-4 family of T cell regulators. PD-1 is expressed on the surface of activated T cells, B cells and macrophages. PD-1 (CD279; Uniprot Q15116) has two ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), which are members of the B7 family.

[0006] CTLA-4 (Uniprot ID No P16410) is expressed on the surface of T helper cells and transmits an inhibitory signal to T lymphocytes. CTLA-4 and CD28 bind to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. CTLA-4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Systemic anti-CTLA-4 treatment has been approved for clinical use and demonstrates clinical benefit. It is being further tested for various other solid cancers (Hodi et al., N Engl J Med 363, 711-723 (2010); Graziani et al., Pharmacol Res (2012) Jan;65(1):9-22). A commercial antibody against CTLA-4 is available under the generic name ipilimumab (marketed as *Yervoy*).

[0007] Various anti-PD-L1 antibodies (e.g. MDX-1105/BMS-936559) and anti-PD-1 antibodies are currently undergoing clinical trials (e.g. MDX-1106/BMS-936558/ONO-4538 or MK-3475/SCH 900475 or AMP-224).

[0008] The glycoprotein immunoglobulin G (IgG) is a major effector molecule of the humoral immune response in man. There are four distinct subgroups of human IgG designated IgG1, IgG2, IgG3 and IgG4. The four subclasses show more than 95% homology in the amino acid sequences of the constant domains of the heavy chains, but differ with respect to structure and flexibility of the hinge region, especially in the number of inter-heavy chain disulfide bonds in this domain. The structural differences between the IgG subclasses are also reflected in their susceptibility to proteolytic enzymes, such as papain, plasmin, trypsin and pepsin.

[0009] Only one isoform of human IgG4 is known. In contrast to human IgG1, IgG2 and IgG3, human IgG4 does not activate complement. Furthermore, IgG4 is less susceptible to proteolytic enzymes compared to IgG2 and IgG3.

[0010] The problem underlying the present invention is the provision of improved means and methods for treating solid cancer, in particular glioma.

[0011] In the course of a study focused on the clinical therapeutic potential of IL-12 in advanced-stage GBM in a relevant rodent model, it was surprisingly found that the combination of IL-12 with a blockade of co-inhibitory signals with anti-CTLA-4 antibody leads to almost complete tumour eradication and cure even at advanced disease stages. The combination of IL-12 with a blockade of co-inhibitory signals with anti-PD-1 antibody as well leads to tumour regression.

[0012] According to a first aspect of the invention, a combination medicament is provided for use in the therapy of solid tumours, particular brain tumours, particularly glioma, which comprises

- an IL-12 polypeptide and
- a T cell inhibition blocker agent selected from
 - a non-agonist CTLA-4 ligand and
 - a non-agonist PD-1 or PD-L1 or PD-L2 ligand.

[0013] In the context of the present invention, an IL-12 polypeptide is a polypeptide having an amino acid sequence comprising the sequence of p35 (Uniprot ID 29459, SEQ ID 05) or a functional homologue thereof, and comprising the sequence of p40 (Uniprot ID29460, SEQ ID 06) or a functional homologue thereof. In one embodiment, the IL-12 polypeptide has an amino acid sequence comprising both p35 and p40 sequences or homologues thereof as part of the same continuous amino acid chain. In another embodiment, the IL-12 polypeptide comprises two distinct amino acid chains, one comprising the p35 sequence and another one comprising the p40 sequence. The terminology "IL-12 polypeptide" does not preclude the presence of non-IL-12 sequences, for example immunoglobulin sequences and fragments thereof, fused to the IL-12 sequences described herein.

[0014] The IL-12 polypeptide has a biological activity of IL-12. A biological activity of IL-12 in the context of the present invention is the stimulation of NK or T cells by said IL-12 polypeptide, most prominently the stimulation of T effector cells acting through perforin.

[0015] In one embodiment of the combination medicament, said IL-12 polypeptide comprises a polypeptide sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of human p35 (SEQ ID 05), and a polypeptide sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of human p40 (SEQ ID 06).

[0016] Identity in the context of the present invention is a single quantitative parameter representing the result of a sequence comparison position by position. Methods of sequence comparison are known in the art; the BLAST algorithm available publicly is an example.

[0017] In one embodiment, said IL-12 polypeptide is a recombinant human IL-12. In one embodiment, said IL-12 polypeptide is a synthetic human IL-12. In one embodiment, said IL-12 polypeptide is a fusion peptide comprising the crystallisable fragment (Fc region) of a human immunoglobulin. According to one embodiment, the IL-12 polypeptide comprises a crystallisable fragment of human immunoglobulin G. A crystallizable fragment in the context of the present invention refers to the second and third constant domain of the IgG molecule. The fragment crystallizable region (Fc region) is the tail region of an immunoglobulin antibody that interacts with cell surface receptors (Fc receptors) and proteins of the complement system. In IgG antibody isotypes, the Fc region is composed of two identical protein fragments, derived from the second and third constant domains of the antibody's two heavy chains.

[0018] According to one embodiment, the IL-12 polypeptide comprises a crystallisable fragment of human immunoglobulin G4. According to one embodiment, the IL-12 polypeptide has or comprises the sequence of SEQ ID 01. According to another embodiment, the IL-12 polypeptide comprises a sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID 01.

[0019] Embodiments wherein IL-12 polypeptide chains are fused to immunoglobulin Fc fragments show different pharmacokinetic behaviour in comparison to the recombinant cytokine, which for some applications may confer a benefit.

[0020] In one embodiment, the IL-12 polypeptide component of the combination medicament is provided as a dosage form for local (intratumoural) administration or delivery. Such dosage form for local (intratumoural) administration may be a slow-release form or depot form, from which said IL-12 polypeptide is released over a number of hours to weeks. In one embodiment, the IL-12 polypeptide component of the combination medicament is administered via convection enhanced delivery (CED) or a variation thereof, for example the device shown in US2011137289 (A1) (incorporated herein by reference).

[0021] In one embodiment, the IL-12 polypeptide is administered systemically together with systemic CTLA-4/PD-1/PD-L1/PD-L2 blockade. Heterodimeric recombinant IL-12 (peprotech) applied systemically together with systemic CTLA-4 blockade (i.p.) achieved a significant improvement in survival in comparison to either agent administered by itself (see Fig. 11).

[0022] In the context of the present invention, a non-agonist CTLA-4 ligand is a molecule that binds selectively to CTLA-4 under conditions prevailing in peripheral blood, without triggering the biological effect of CTLA-4 interaction with any of the physiological ligands of CTLA-4, particularly CD80 and/or CD86.

[0023] In the context of the present invention, a non-agonist PD-1 ligand is a molecule that binds selectively to PD-1 under conditions prevailing in peripheral blood, without triggering the biological effect of PD-1 interaction with any of the physiological ligands of PD-1, particularly PD-L1 or PD-L2. A non-agonist PD-L1 (PD-L2) ligand is a molecule that binds selectively to PD-L1 (or to PD-L2) under conditions prevailing in peripheral blood, without triggering the biological effect of PD-L1 (PD-L2) interaction with any of its physiological ligands, particularly PD-1.

[0024] In some embodiments, said non-agonist CTLA-4 ligand is a polypeptide binding to CTLA-4. In some embodiments, said non-agonist PD-1 ligand is a polypeptide binding to PD-1.

[0025] A non-agonist CTLA-4 ligand in the sense of the invention refers to a molecule that is capable of binding to CTLA-4 with a dissociation constant of at least 10^{-7} M⁻¹, 10^{-8} M⁻¹ or 10^{-9} M⁻¹ and which inhibits the biological activity of its respective target. A non-agonist PD-1 ligand or a non-agonist PD-L1 (PD-L2) ligand in the sense of the invention refers to a molecule that is capable of binding to PD-1 (PD-L1, PD-L2) with a dissociation constant of at least 10^{-7} M⁻¹, 10^{-8} M⁻¹ or 10^{-9} M⁻¹ and which inhibits the biological activity of its respective target.

[0026] A non-agonist polypeptide ligand may be an antibody, an antibody fragment, an antibody-like molecule or an oligopeptide, any of which binds to and thereby inhibits CTLA-4, PD-1 or PD-L1 (PD-L2), respectively.

[0027] An antibody fragment may be a Fab domain or an Fv domain of an antibody, or a single-chain antibody fragment, which is a fusion protein consisting of the variable regions of light and heavy chains of an antibody connected by a peptide linker. The inhibitor may also be a single domain antibody, consisting of an isolated variable domain from a heavy or light chain. Additionally, an antibody may also be a heavy-chain antibody consisting of only heavy chains such as antibodies found in camelids. An antibody-like molecule may be a repeat protein, such as a designed ankyrin repeat protein (Molecular Partners, Zurich).

[0028] An oligopeptide according to the above aspect of the invention may be a peptide derived from the recognition site of a physiological ligand of CTLA-4, PD-1 or PD-L1 or PD-L2. Such oligopeptide ligand competes with the physiological ligand for binding to CTLA-4, PD-1 or PD-L1 or PD-L2, respectively.

[0029] Particularly, a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand or non-agonist PD-L1 ligand or non-agonist PD-L2 ligand does not lead to attenuated T cell activity when binding to CTLA-4, PD-1, PD-L1 or PD-L2, respectively, on the surface on a T-cell. In certain embodiments, the term "non-agonist CTLA-4 ligand" or "non-agonist PD-1 ligand" covers both antagonists of CTLA-4 or PD-1 and ligands that are neutral vis-à-vis CTLA-4 or PD-1 signalling. In some embodiments, non-agonist CTLA-4 ligands used in the present invention are able, when bound to CTLA-4, to sterically block interaction of CTLA-4 with its binding partners CD80 and/or CD86 and non-agonist PD-1 used in the present invention are able, when bound to PD-1, to sterically block interaction of PD-1 with its binding partners PD-L1 and/or PD-L2.

[0030] In one embodiment, said non-agonist CTLA-4 ligand is a gamma immunoglobulin binding to CTLA-4, without triggering the physiological response of CTLA-4 interaction with its binding partners CD80 and/or CD86.

[0031] In some embodiments, said non-agonist PD-1 ligand is a gamma immunoglobulin binding to PD-1, without triggering the physiological response of PD-1 interaction with its binding partners PD-L1 and/or PD-L2.

[0032] In some embodiments, said non-agonist PD-L1 (PD-L2) ligand is a gamma immunoglobulin binding to PD-L1 (PD-L2), without triggering the physiological response of PD-1 interaction with its binding partners PD-L1 and/or PD-L2.

[0033] Non-limiting examples for a CTLA-4 ligand are the clinically approved antibodies tremelimumab (CAS 745013-59-6) and ipilimumab (CAS No. 477202-00-9; Yervoy).

[0034] Non-limiting examples for a PD-1 / PD-L1 or PD-L2 are the antibodies MDX-1105/BMS-936559, MDX-1106/BMS-936558/ONO-4538, MK-3475/SCH 900475 or AMP-224 currently undergoing clinical development

[0035] The term "gamma immunoglobulin" in this context is intended to encompass both complete immunoglobulin molecules and functional fragments thereof, wherein the function is binding to CTLA-4, PD-1 or PD-L1 (PD-L2) as laid out above.

[0036] In one embodiment, the combination therapy comprises two distinct dosage forms, wherein said IL-12 polypeptide is provided as a dosage form for intratumoural delivery or local delivery in the vicinity of the tumour, and said non-agonist CTLA-4 ligand or non-agonist PD-1 ligand is provided as a dosage form for systemic delivery, particularly by intravenous injection. However, said non-agonist CTLA-4 ligand or non-agonist PD-1 ligand may also be locally applied in the same way as the IL-12 polypeptide. According to another embodiment, the IL-12 polypeptide is applied directly to the tumour draining lymph node.

[0037] According to another embodiment, the combination therapy comprises a dosage form whereby said IL-12 polypeptide is provided for intracranial delivery, e.g. by injection.

[0038] According to another aspect of the invention, a combination medicament is provided as set forth above, for use in a method of therapy of a malignant neoplastic disease, particularly solid cancerous lesions. In one embodiment, the malignant neoplastic disease is glioma. In one embodiment, the malignant neoplastic disease is a secondary brain tumour (brain metastasis of a neoplastic lesion arising outside the brain). In one embodiment, the disease is glioblastoma multiforme. In one embodiment, the malignant neoplastic disease is meningioma. In one embodiment, the malignant neoplastic disease is melanoma. In one embodiment, the malignant neoplastic disease is pancreatic cancer. In one embodiment, the malignant neoplastic disease is lung cancer. In one embodiment, the malignant neoplastic disease is prostate cancer. In one embodiment, the malignant neoplastic disease is bladder cancer.

[0039] Cancerous lesions have the propensity to spread into neighbouring tissue as well as distinct locations in the body, depending on their origin. 20-40% of all cancers develop brain metastasis; among those lung, breast and skin (melanoma) cancer are the most common sources of brain metastases (Sofietti et al., J Neurol 249, 1357-1369 (2002)). Similar to primary malignant brain tumours, brain metastases have a poor prognosis despite treatment and are quickly fatal. T-cells are the crucial effector cell population for IL-12 mediated tumor rejection in the brain. IL-12 together with anti-CTLA-4, anti-PD-1, anti-PD-L1 or anti-PD-L2 combination treatment addresses especially the T-cells to activate and repolarize them. Since brain metastases grow in the same immune-compartment as primary brain tumors, patients suffering from secondary brain tumors also benefit from the combination treatment.

[0040] In one embodiment, the combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 provided as a fusion protein comprising the amino acid of human p40, the amino acid sequence of human p35 and the crystallisable fragment of human IgG4, said IL-12 polypeptide being formulated as a dosage form for intratumoural delivery. According to this embodiment, the combination medicament further comprises an immunoglobulin G raised

against CTLA-4 or PD-1 as a non-agonist CTLA-4 ligand and/or a non-agonist PD-1 ligand formulated as a dosage form for systemic delivery. According to this embodiment, the combination medicament is provided for the treatment of malignant neoplastic disease, particularly for glioma, glioblastoma multiforme, meningioma, melanoma, pancreatic cancer, lung cancer, prostate cancer or bladder cancer.

[0041] According to yet another aspect of the invention, an IL-12 polypeptide having a biological activity of IL-12, and a non-agonist CTLA-4 ligand and/or non-agonist PD-1 ligand are used in the manufacture of a combination medicament for use in a method of therapy of a malignant neoplastic disease, particularly of glioma and other solid tissue tumours, such as glioblastoma multiforme, meningioma, melanoma, pancreatic cancer, lung cancer, prostate cancer or bladder cancer.

[0042] According to yet another aspect of the invention, a method is provided for treating a patient suffering from malignant neoplastic disease, particularly glioma and other solid tissue tumours, comprising the administration of an IL-12 polypeptide having a biological activity of IL-12, and a non-agonist CTLA-4 ligand and/or a non-agonist PD-1 ligand to said patient.

[0043] According to an alternative aspect of the invention, a combination therapy comprises an IL-12 nucleic acid expression vector encoding an encoded IL-12 polypeptide having a biological activity of IL-12, and a T cell inhibition blocker agent selected from

- a non-agonist CTLA-4 ligand and
- a non-agonist PD-1 or PD-L1 or PD-L2 ligand.

[0044] The CTLA-4 ligand and a non-agonist PD-1 ligand may be embodied by polypeptides, particularly by antibodies, as set forth above. One non-limiting example for an encoded IL-12 polypeptide is a crystallisable immunoglobulin G fragment fused to the IL-12 constituent polypeptide chains, human IL-12 or a functional equivalent thereof. One non-limiting example is a fusion construct having the constituent polypeptides of IL-12 linked by a short amino acid sequence as depicted in Fig. 1, the amino acid sequence for which is given as SEQ ID 01 and the encoding nucleic acid sequence is given as SEQ ID 07.

[0045] According to yet another aspect of the invention, a polypeptide peptide is provided comprising

- a. a polypeptide sequence at least 95% identical to the sequence of human p35 (SEQ ID 05), and
- b. a polypeptide sequence at least 95% identical to the sequence of human p40 (SEQ ID 06) and
- c. a human immunoglobulin G subgroup 4 crystallisable fragment.

[0046] In some embodiments, the polypeptide comprises or essentially consists of a sequence at least 95%, 96%, 97%, 98%, 99% identical to SEQ ID 01, or is SEQ ID 01.

[0047] The advantage of using fusion proteins cytokines and the crystallisable fragment of immunoglobulins rather than the recombinant cytokine is improved pharmacokinetics (Belladonna et al. J Immunol 168, 5448-5454 (2002); Schmidt, Curr Opin Drug Discov Devel 12, 284-295 (2009); Eisenring et al., Nat Immunol 11, 1030-1038 (2010)).

[0048] The IL-12 nucleic acid expression vector according to this aspect of the invention may, by way of non-limiting example, be a "naked" DNA expression plasmid comprising a nucleic acid sequence encoding the IL-12 polypeptide under control of a promoter sequence operable in a human tumour cell, for delivery into the tumour, for example by intracranial injection. The IL-12 nucleic acid expression vector may similarly be a viral vector, for example an adeno-associated virus, an adenovirus, a lentivirus or a herpes virus.

[0049] Such IL-12 nucleic acid expression vector may be provided as a dosage form for intratumoural delivery in combination with a protein non-agonist CTLA-4 ligand and/or a non-agonist PD-1 ligand as set forth above. Similarly, the scope of the present invention encompasses the use of such IL-12 nucleic acid expression vector, in combination with a non-agonist CTLA-4 ligand and/or a non-agonist PD-1 ligand, in a method of making a combination medicament for use in therapy of malignant neoplastic disease, particularly glioma, glioblastoma multiforme, meningioma, melanoma, pancreatic cancer, lung cancer, prostate cancer or bladder cancer. Likewise, a method is provided for treating a patient suffering from malignant neoplastic disease, particularly glioma or other solid tissue tumours, comprising the administration of an IL-12 nucleic acid expression vector having a biological activity of IL-12, and a non-agonist CTLA-4 ligand and/or a non-agonist PD-1 ligand to said patient.

Brief description of the Figures

[0050]

Fig. 1a shows the structure and sequence of the fusion protein given in SEQ ID 01. The subunits p40 and p35 of IL-12 are depicted as rectangles. These subunits are connected by a linker (G₄S)₃. The subunits CH2, CH3 and the last six amino acids of CH1 of the crystallizable fragment of the immunoglobulin are shown as oblong circles.

Fig. 1b shows the fusion protein given SEQ ID 01, left picture shows an immunoblot using reducing conditions, developed with an HRP-coupled polyclonal anti-human Fc antibody, right picture shows a silver staining of the fusion protein under non-reducing (DTT -) and reducing conditions (DTT +)

Fig. 1c shows IFN- γ production in human peripheral blood monocytic cells (PBMCs) as assessed by enzyme linked immunosorbent assay (ELISA). Cells were stimulated either with commercially available heterodimeric recombinant human IL-12 (rhIL-12) or with the purified fusion protein given SEQ ID 01 (hIL-12Fc) in the presence of an antibody directed against CD3 (polyclonal T-cell stimulation). Unstimulated: neither IL-12 stimulation nor anti-CD3 stimulation (baseline control). Experiment was performed in triplicates, error bars denote s.e.m. data representative of three independent experiments

Fig. 2 shows immunohistochemistry of formalin fixed tumour sections obtained from syngeneic C57/Bl6 mice 5 weeks after challenge with 2x10⁴ GI261 IL-12Fc or GI261 Fc cells and stained with antibody against F4/80, counterstain hematoxylin (representative examples, n=6 mice per group). Scale bar indicates 2 mm, arrowhead indicates residual GI261 IL-12Fc (SEQ ID 02) tumour.

Fig. 3 shows non-invasive Bioluminescence imaging (BLI) of mouse glioma in syngeneic C57/Bl6 mice (n = 5-6 mice per group) after implantation of 2x10⁴ GI261 cells constitutively expressing *photinuspyralis* luciferase and releasing a fusion protein of IL-12 and the crystallizable fragment of mouse immunoglobulin G3 (GI261 IL-12Fc, (SEQ ID 02)) or Fc alone as control (GI261 Fc). Upper panel: Quantification of tumour growth which correlates to photon flux (p/s) in the region of interest (ROI) versus the days post injection of the modified glioma cells. Lower panel: Kaplan-Meier survival analysis. Data are representative of 2 independent experiments.

Fig. 4 shows non-invasive Bioluminescence (BLI) imaging of mouse glioma in WT animals and different mouse mutants (n = 5-7 mice per group) after implantation of 2x10⁴ GI261 cells constitutively expressing *photinuspyralis* luciferase and releasing a fusion protein of IL-12 and the crystallizable fragment of mouse immunoglobulin G3 (GI261 IL-12Fc, (SEQ ID 02)). Upper panel: Quantification of tumour growth via BLI imaging versus the days post injection of the modified glioma cells. Lower panel: Kaplan-Meier survival analysis. **A)** GI261 IL-12Fc were implanted in mice lacking T and B cells (*Rag1*^{-/-}) or NK cells (*IL-15ra*^{-/-}) or lacking both T-, B-, NK cells and lymphoid tissue inducer like cells (*Rag2*^{-/-} *Il2rg*^{-/-}). **B)** GI261 IL-12Fc were implanted in mice deficient for MHCII (*Ia(b)*^{-/-}) and MHCI (*β 2m*^{-/-}). (n=5-8 mice/group), lacking CD4 or CD8 positive T-cells, respectively. Data are representative of 2 independent experiments.

Fig. 5 shows T cell memory formation in surviving wt animals that had been previously challenged with 2x10⁴ GI261 IL-12Fc (SEQ ID 02) cells. Examples for bioluminescence emitted from the brains of surviving wt animals that had been rechallenged with GI261 Fc cells compared to naïve wt animals is shown (upper panel, days 1, 7 and 21 post rechallenge shown). Furthermore, bioluminescence of the tumours is shown in photons per second (p/s) in the region of interest (ROI) versus the days post injection of the modified glioma cells (lower panel). A rapid rejection of the control tumours in surviving wt animals was observed. While the measured luminescence at day 1 suggested identical seeding across the two groups, only the naïve mice exhibited a measurable signal at day 7 onwards, suggesting a rapid and effectively clearing anti-glioma memory response now independent of ectopically expressed pro-inflammatory cytokines (namely IL-12Fc, (SEQ ID 02)). (n=4-6 mice/group). Data are representative of 2 independent experiments.

Fig. 6 shows non-invasive Bioluminescence (BLI) imaging of mouse glioma in different mouse mutants (n = 4-8 mice per group) after implantation of 2x10⁴ GI261 Fc cells constitutively expressing *photinuspyralis* luciferase and releasing a fusion protein of IL-12 and the crystallizable fragment of mouse immunoglobulin G3 (GI261 IL-12Fc (SEQ ID 02)). **A)** wt (open circles) and *IFN γ* ^{-/-} (black circles) animals **B)** wt (open circles) and *Perforin*^{-/-} (black circles) animals. Quantification of tumour growth which correlates to photon flux (p/s) in the region of interest (ROI) versus the days post injection of the modified glioma cells are shown (upper panel). Lower panel: Kaplan-Meier survival analysis. Data are representative of 2 independent experiments.

Fig. 7 shows tumour growth in wt mice inoculated with 2x10⁴ GI261 Fc cells. Treatment started at day 21 (arrows).

Osmotic minipumps delivering IL-12Fc (SEQ ID 02) (or PBS) into the tumour were implanted into glioma bearing animals. Animals received i.p. injections of α CTLA-4 blocking antibodies or PBS starting at day 22, followed by injections as indicated in figure. Upper graph: quantification of ROI photon flux of tumour bearing wt animals receiving the indicated treatment. Lower graph: Kaplan-Meier survival analysis of the animals above; PBS/PBS vs IL-12Fc/ α CTLA-4 $p=0.0045$, PBS/PBS vs IL-12Fc/PBS $p=0.3435$, PBS/ α CTLA4 vs IL-12Fc/ α CTLA-4 $p=0.0101$; Log-rank (Mantel-Cox) Test. Data representative of three independent experiments with 2-5 animals per group

Fig. 8 shows immunohistochemistry of tumour sections obtained from syngenic C57/BI6 mice after challenge with GI261 Fc cells at day 21 and after local administration of IL-12Fc (SEQ ID 02) in combination with systemic CTLA-4 blockade as described in Example 5. The sections were stained with Hematoxylin and Eosin. Scale bar indicates 2 mm.

Fig. 9 shows tumour growth in wt mice inoculated with 2×10^4 GI261 Fc cells. Treatment started at day 21 (arrows). Osmotic minipumps delivering IL-12Fc (SEQ ID 02) into the tumour were implanted into glioma bearing animals. Animals received i.p. injections of α PD-1 blocking antibodies or isotype control antibodies starting at day 22, followed by injections as indicated in figure. Upper graph: quantification of ROI photon flux of tumour bearing wt animals receiving the indicated treatment. Lower graph: Kaplan-Meier survival analysis of the animals above; PBS/isotype vs IL-12Fc/ α PD-1 $p=0.0064$, Log-rank (Mantel-Cox) Test. Data representative of one experiment with 5-6 animals per group.

Fig. 10 shows tumour growth in wt mice inoculated with 50 B16-F10 cells. Treatment started at day 5 (arrow). Osmotic minipumps delivering IL-12Fc (SEQ ID 02) into the tumour were implanted into glioma bearing animals. Animals received i.p. injections of α CTLA-4 blocking antibodies or PBS starting at day 6, followed by injections as indicated in figure. Kaplan-Meier survival analysis PBS/PBS vs IL-12Fc/ α CTLA-4 $p=0.0028$, Log-rank (Mantel-Cox) Test. Data representative of one experiment with 6 animals per group.

Fig. 11 shows systemic administration of recombinant heterodimeric IL-12 in combination with CTLA4 blockade 2×10^4 GI261 Fc cells were injected into the right striatum of wt mice and tumor growth was followed for 90 days. Systemic treatment: at day 21 (arrow), tumor bearing animals were treated initially with $200 \mu\text{g}$ α CTLA-4 mouse IgG2b (9D9) (filled light grey triangles, $n=8$), 200 ng of recombinant heterodimeric IL-12 (rIL-12) (filled dark grey triangles, $n=9$) or a combination of both (filled black triangles, $n=9$) injected intraperitoneal (i.p.). The control group received phosphate buffered saline (PBS) (filled open triangles, $n=7$). Treatment was sustained with $100 \mu\text{g}$ α CTLA-4 or 100 ng rIL-12 or a combination of both 3 times / week until the end of the experiment. Upper graph: quantification of ROI photon flux of tumor bearing wt animals receiving the indicated treatment. Lower graph: Kaplan-Meier survival analysis of the animals above; Log-rank (Mantel-Cox) Test was used to calculate the p-values indicated; Pooled data from two independent experiments.

Examples

Methods

Animals

[0051] C57BL/6 mice were obtained from Janvier; $b2m^{-/-}$, $la(b)^{-/-}$, $Il12rb2^{-/-}$, $Rag1^{-/-}$, $Rag2^{-/-}Il2rg^{-/-}$, $Prf1^{-/-}$ and $Ifng^{-/-}$ mice were obtained from Jackson Laboratories. $Il5ra^{-/-}$ mice were provided by S. Bulfone-Paus. All animals were kept in house under specific pathogen-free conditions at a 12hour light/dark cycle with food and water provided *ad libitum*. All animal experiments were approved by the Swiss Cantonal veterinary office (16/2009).

Mouse tumour cell lines

[0052] C57/BI6 murine glioma (GI261) cells (kindly provided by A. Fontana, Experimental Immunology, University of Zurich) were transfected with pGI3-ctrl (Promega) and pGK-Puro (kindly provided by T. Buch, Technical University Munich). Linearized constructs were electroporated in a 10:1 ratio using an eppendorf multiporator, then selected with $0.8 \mu\text{g/ml}$ puromycin (Sigma-Aldrich) to generate luciferase-stable GI261 cells. A single clone was isolated by limiting dilution and passaged in vivo by intracranial tumour inoculation, followed by tumour dissociation after 4 weeks and re-selection in $0.8 \mu\text{g/ml}$ puromycin. Subsequently, cells were electroporated with pCEP4-mIgG3, pCEP4-mIL-12mIgG3 (SEQ ID 09) and pCEP4-mIL-23mIgG3 (SEQ ID 08) (Eisenring et al, 2010) and bulk-selected with $0.8 \mu\text{g/ml}$ puromycin

and 0.23mg/ml hygromycin (Sigma-Aldrich). Cytokine production was detected by ELISA (OptEIA IL-12/23p40, BD Pharmingen) and rt-PCR (IgG3fw: ACACACAGCCTGGACGC (SEQ ID 03) IgG3rev: CATTGAACTCCTTGCCCCCT (SEQ ID 04)). GI261 cells and derived cell lines were maintained in Dulbecco's modified Eagle's medium (Gibco, Invitrogen) supplemented with 10% fetal calf serum (FCS) in presence of selection antibiotics as indicated above at 37°C and 10% CO₂. B16-F10 murine melanoma cells were purchased from ATCC.

Expression and purification of IL-12Fc

[0053] IL-12Fc (SEQ ID 02) was expressed in 293T cells after calcium phosphate-mediated transfection according to standard protocols with 45µg of vector DNA (pCEP4-mIL-12IgG3, SEQ ID 09)/15cm tissue culture plate. Supernatant was harvested 3 days and 6 days after transfection, sterile filtered and diluted 1:1 in PBS. The protein was purified using a purifier (ÄktaPrime) over a protein G column (1ml, HiTrap, GE Healthcare) eluted with 0.1 M glycine pH 2 and dialyzed over night in PBS pH 7.4. Concentration and purity of IL-12Fc (SEQ ID 02) was measured by ELISA (OptEIA IL-12/23p40, BD Pharmingen) and SDS-PAGE followed by silverstaining and immunoblotting. IL-12Fc was detected with a rat anti mouse IL-12p40 antibody (C17.8, BioExpress) and a goat anti-rat HRP coupled antibody (Jackson). The same procedure was used for the expression of human IL-12Fc (SEQ ID 01, 07).

Characterization of human IL-12Fc

[0054] Concentration and purity of human IL-12Fc (SEQ ID 01) was measured by ELISA (Human IL-12 (p70), Mabtech, #2455-1H-6) and SDS-PAGE followed by silver staining and immunoblotting. The human IgG4 tag was detected with an HRP-coupled goat anti human IgG antibody (#A0170, Sigma). For functional characterization of human IL-12Fc (SEQ ID 01) PBMCs, acquired according to the ethical guidelines of the University of Zurich, were plated at 100'000 cells per well in RPMI medium supplemented with 10% fetal calf serum (FCS) in 96 well plates and stimulated with either recombinant human IL-12 (Peprotech) or human IL-12Fc (SEQ ID 01). Both cytokines were normalized to each other according to concentrations derived from human IL-12p70 ELISA (Mabtech, #2455-1 H-6). PBMCs were stimulated in the presence of 1µg/ml of a mouse IgG2a anti-human CD3 antibody (OKT3, Bio-X-cell). After two days of culture in 5% CO₂ and 37°C, supernatant was harvested and subjected to an anti-human IFN-γ ELISA (Mabtech, #3420-1 H-6).

Orthotopic glioma inoculation

[0055] Briefly, 6-10 week old mice were i.p. injected with Flunixin (Biokema, 5mg/kg body weight) before being anaesthetized with 3-5% isoflurane (Minrad) in an induction chamber. Their heads were shaved with an electric hair-trimmer. After being mounted onto a stereotactic frame (David Kopf Instruments), the animals' scalp was disinfected with 10% iodine solution and a skin incision was made along the midline. Anaesthesia on the stereotactic frame was maintained at 3% isoflurane delivered through a nose adaptor (David Kopf Instruments). Subsequently, a blunt ended syringe (Hamilton, 75N, 26s/2"/2, 5µl) was mounted on a microinjection pump on the manipulator arm and placed 1.5mm lateral and 1 mm frontal of bregma. The needle was lowered into the manually drilled burr hole at a depth of 4mm below the dura surface and retracted 1 mm to form a small reservoir. Using the microinjection pump (UMP-3, World Precision Instruments Inc.) 2x10⁴ cells were injected in a volume of 2µl at 1 µl/min. After leaving the needle in place for 2min, it was retracted at 1 mm/min. The burr hole was closed with bone wax (Aesculap, Braun) and the scalp wound was sealed with tissue glue (Indermil, Henkel).

In vivo bioluminescent imaging

[0056] Tumour bearing mice were carefully weighed, anaesthetized with isoflurane (2-3%) and injected with D-Luciferin (150mg/kg body weight, CaliperLifesciences). Animals were transferred to the dark chamber of a Xenogen IVIS 100 (CaliperLifesciences) imaging system, anaesthesia was maintained at 2% isoflurane via nosecones. 10min after injection luminescence was recorded. Data was subsequently analyzed using Living Image 2.5 software (CaliperLifesciences). A circular region of interest (ROI; 1.46cm Ø) was defined around the animals' head and photon flux of this region was read out and plotted.

Treatment of established gliomas

[0057] At d21 after implantation of the glioma cells, the tumour bearing animals were evenly distributed among experimental groups based on their ROI-photon flux. Animals with an ROI flux of less than 1x10⁵ p/s were considered as non-takers and excluded. 40-48h prior to implantation (2 days before beginning of treatment), osmotic pumps (Model 2004, 0.25µl/h; Alzet) were filled with murine IL-12Fc (SEQ ID 02, 8.33 ng/µl in PBS) or PBS alone and primed at 37°C in

PBS. Immediately prior to surgery, mice were injected with Flunixinip. (Biokema, 5mg/kg body weight). Mice were anaesthetized with 3-5% isoflurane, the scalp was disinfected and a midline incision was made. The previous burr hole of the glioma injection was located, the bone wax and periosteum removed and the pump placed into a skin pouch formed at the animal's back. The infusion cannula was lowered through the burr hole 3mm into the putative center of the tumour. The cannula was connected to the pump (brain infusion kit III 1-3mm, Alzet) via a silicon tube and held in place with cyanoacrylate adhesive. The skin was sutured with a 4-0 nylon thread. Following surgery, mice were treated for 3 days with 0.1 % (v/v) Borgeal (Intervet) in the drinking water. Pumps were explanted at day 49. Five doses of anti mouse-CTLA-4 mouse-IgG2b antibodies (clone 9D9, bio-X-cell; Peggs et al.; J Exp Med 206, 1717-1725 (2009)) or an equivalent volume of PBS were i.p. injected at days 22 (200µg), 26 (100µg), 29 (100µg), 35 (100µg) and 42 (100µg).

[0058] Alternatively, animals received anti-mouse-PD-1 rat IgG2a (clone RMP1-14, bio-X-cell) or rat IgG2a isotype control antibodies (clone 2A3, bio-X-cell) for the experiment depicted in figure 9. Dosing schedule and application route was identical with the experiment depicted in figure 7. For treatment of established B16-F10 derived brain tumours, pumps were implanted at day 5 post injection, anti mouse-CTLA-4 mouse-IgG2b antibodies (clone 9D9, bio-X-cell; Peggs et al.; J Exp Med 206, 1717-1725 (2009)) or an equivalent volume of PBS were i.p. injected at days 6 (200µg), 11 (100µg), 13 (100µg) and 19 (100µg).

Survival analysis of tumour bearing animals

[0059] Tumour bearing animals were monitored by BLI, checked for neurological symptoms and weighed weekly until day 21 post glioma inoculation. GI261 Fc animals exhibiting an ROI flux of less than 1×10^5 p/s at day 21 were considered as non or slow-tumour takers and excluded from the survival analysis (5-10%). From day 21 onwards animals were checked daily. Animals that showed symptoms as apathy, severe hunchback posture and/or weight loss of over 20% of peak weight were euthanized. B16-F10 tumour bearing mice were scored daily starting at day 5 until the end of experiment according to the same scheme.

Histology

[0060] For histology, animals were euthanized with CO₂, transcardially perfused with ice-cold PBS and decapitated. Whole brains were carefully isolated, fixed in 4% Formalin, embedded in Paraffin and 3µm sections were processed for HE staining and/or immunohistochemistry to detect F4/80 (BM8; BMA biomedical). Primary antibodies were detected with HorseRadish Peroxidase- coupled secondary antibodies. Staining was visualized with 3,3'-Diaminobenzidine (DAB) as the HRP substrate. Pictures were generated using an Olympus BX41 light microscope equipped with an Olympus ColorViewillu camera and Olympus cell^B image acquisition software. Overviews of whole brains slices were cropped using Adobe Photoshop CS3.

Statistical analysis

[0061] For statistical analysis of Kaplan-Meier survival curves, a Log-rank (Mantel-Cox) Test was used to calculate the p-values indicated in respective figures. P values of less than 0.05 were considered statistically significant. Analysis was performed with GraphPad Prism version 5.0a for Mac OSX (GraphPad Software Inc).

Example 1: Intratumoural expression of IL-12Fc promotes clearance of experimental gliomas

[0062] We have designed and cloned a fusion protein consisting of the p40 subunit of human IL-12 linked via a flexible peptide linker to the p35 subunit. This single chain construct was then fused to the constant region of human IgG4 heavy chain (Fig. 1A). We termed this human single chain fusion protein IL-12Fc (SEQ ID 01.) We expressed this protein in HEK293 human embryonic kidney cells and detected a dimeric as well as a monomeric form under native conditions. Under reducing conditions only the monomeric form is detectable (Fig. 1 B). IL-12Fc (SEQ ID 01) has similar functional properties as commercially available heterodimeric IL-12 (purchased from Peprotech). To determine if IL-12Fc (SEQ ID 01) could be suitable to overcome the local immunosuppressive environment induced by gliomas and to shed light on the effector mechanisms involved, we expressed a murine version (Belladonna et al. J Immunol 168, 5448-5454 (2002), IL-12Fc (SEQ ID 02)) of this cytokine in GI261 mouse glioma cells. To measure intracranial tumour growth non-invasively via bioluminescence imaging (BLI) we first generated a GI261 line that constitutively expresses *photinus pyralis* luciferase. We termed this cell line GI261-luc. We next modified this cell line to continuously release a fusion protein of IL-12 and the crystallizable fragment of mouse immunoglobulin G3 (IL-12Fc; SEQ ID 02, 09) or Fc (SEQ ID 08) alone as a control (termed 'GI261 IL-12Fc' and 'GI261 Fc', respectively). The chosen murine protein sequence of the fusion construct is homologous to the human variant (SEQ ID 01) and consists of the subunits p40 and p35 of IL-12 which are connected by a linker (G4S)₃ and the subunits CH2, CH3 and the last six amino acids of CH1 of the crystallizable fragment of IgG3,

whereas CH1 and CH2 are connected by a hinge region. Vectors for expression of the control fragment and the IL-12 fusion construct are depicted in SEQ ID 08 and 09, respectively. The intention of using fusion proteins rather than the recombinant cytokine was to see whether they would exhibit improved pharmacokinetics. We confirmed secretion of IL-12Fc (SEQ ID 02) by ELISA for the subunits p40 and p70. We further confirmed expression of the Fc tail by RT-PCR.

When implanted intracranially into the right striatum, luminescence readings and tumour volume as assessed by stereologic methods showed a robust correlation (data not shown).

[0063] We next implanted GI261 IL-12Fc and Fc into the right striatum of syngenic C57Bl/6 mice and followed tumour growth via non invasive bioluminescence imaging (BLI). After an initial increase in luminescence all groups showed a depression around day 14 post injection. Animals bearing Fc-expressing tumours exhibited a steep increase in BLI and soon reached withdrawal criteria, sometimes even before day 35 post injection. In contrast, BLI-readings for animals that had been injected with IL-12Fc expressing GI261 tumours dropped to levels close to the detection limit at day 21 onwards (data not shown). In agreement with this observation, we could only detect a residual tumour in some animals in this group, while Fc control-injected animals showed robust tumour formation when analyzed histologically (Fig. 2). When we followed animals that had been implanted with GI261 IL-12Fc or GI261 Fc cells for up to 90 days, we observed rejection of the tumour in a high proportion of mice bearing IL-12Fc secreting tumours after an initial establishment (Fig. 3).

Example 2: T-cells are the major effector cell type of IL-12Fc mediated glioma rejection.

[0064] To confirm that the secretion of IL-12Fc by GI261 IL-12Fc acts on the host rather than the tumour cells themselves, we observed the growth of GI261 IL-12Fc and GI261 Fc to be the same in mice lacking the receptor to IL-12. The unbridled growth of GI261 IL-12 in *IL-12 α β 2^{-/-}* animals demonstrates that IL-12Fc acts specifically on a cell type in the recipient mouse (data not shown). T and NK cells are among the most prominent IL-12 responsive leukocytes. To systematically test the functional relevance of the IL-12Fc mediated influx of these cells, we challenged a series of mouse mutants with intracranial GI261 IL-12Fc. We implanted GI261 IL-12Fc cells in mice that lack T and B cells (*Rag1^{-/-}*) or conventional Nk-cells (*IL-15 α ^{-/-}*) or in mice lacking both T-, B-, Nk-cells and lymphoid tissue inducer-like cells (*Rag2^{-/-} IL2 γ ^{-/-}*) (Fig. 4A). After an initial lag phase until day 14 after injection, all groups exhibited a strong increase in luminescence until day 28, reflecting strong tumour growth. Between days 28 and 42 most of the animals succumbed to the tumours. Only wt and *IL-15 α ^{-/-}* mice were able to control the tumour and show a significantly prolonged survival compared to *Rag2^{-/-} IL2 γ ^{-/-}* and *Rag1^{-/-}* animals. While T or B-cells appeared to be crucial for IL-12Fc mediated glioma rejection, the ability of *IL-15 α ^{-/-}* mice to reject GI261 IL-12 indicates that NK cells were largely expendable.

[0065] We next investigated the contribution of CD4- and CD8 positive T-cells using MHCII (*Ia(b)^{-/-}*) and MHCI (*β 2m^{-/-}*) deficient mice. In contrast to wt mice, *Ia(b)^{-/-}* mice lacking CD4 T cells could not control GI261 IL-12Fc tumours, and *β 2m^{-/-}* mice succumbed to the glioma shortly afterwards (Fig. 4B). The survival in both mutant groups was shortened compared to the wildtype group. These data clearly demonstrate that IL-12Fc mediated tumour rejection is dependent on the activity of T cells including helper T cells and CTLs.

Example 3: The antitumoural memory response is independent of ectopically expressed IL-12Fc.

[0066] To further investigate the character of the T-cell dependent tumour control, we tested the surviving wt animals that had been previously challenged with GI261 IL-12Fc cells for T cell memory formation (Fig. 5). The animals were treated as described in Fig. 3 / example 1. In contrast to the primary challenge, we now injected GI261 Fc cells into the contralateral hemisphere of survivors or naïve wt animals. We observed a rapid rejection of the control tumours within days. While the measured luminescence at day 1 suggested identical seeding across the two groups, only the naïve mice exhibited a measurable signal at day 7 onwards, suggesting a rapid and effectively clearing anti-glioma memory response now independent of ectopically expressed pro-inflammatory cytokines.

Example 4: CTLs are the main effector cells of IL-12Fc-mediated glioma rejection.

[0067] It is well established that IL-12 polarizes naïve T-cells to adopt a T_H1 phenotype (Trinchieri, Nat Rev Immunol 3, 133-146 (2003)). To shed further light on the mechanistic underpinnings underlying the IL-12 induced rejection of experimental glioma, we challenged mice deficient in the T_H1 hallmark cytokine IFN- γ (*Ifng^{-/-}*) with IL-12Fc expressing GI261 cells (Fig. 6A). The animals were treated as described in Fig. 3/ Example 1. To our surprise we observed a similar tumour rejection as in wt animals, suggesting that the mechanism of rejection is independent of IFN- γ . Conversely, IL-12 also stimulates the cytotoxic activity of CTLs. When we analyzed the role of Perforin, a cytolytic molecule primarily expressed on CD8⁺ CTLs and Nk-cells, we observed a clear difference in survival curves. (Fig. 6B). Perforin is a cytolytic molecule primarily expressed by CD8⁺ CTLs and NK cells but also CD4⁺ T-cells. To further investigate the mechanism of IL-12Fc induced rejection of glioma, perforin-deficient mice (*prf1^{-/-}*) were challenged with IL-12Fc expressing GI261

cells. In contrast to *Ifng*^{-/-}, Perforin deficient animals (*prf1*^{-/-}) were not able to control the tumour. This further supports the notion that CTLs are the main effector cells of IL-12Fc mediated glioma rejection. A clear difference in the survival curves of wt and *prf1*^{-/-} was observed.

Example 5: Local administration of IL-12Fc in combination with systemic CTLA-4 blockade is effective against advanced stage experimental gliomas

[0068] To further boost and prolong the activated phenotype of T-cells, we blocked the co-inhibitory molecule CTLA-4 via neutralizing antibodies in the next set of experiments. IL-12 was administered locally to mice with advanced stage tumours. Treatment was administered to animals that had been challenged with GI261 Fc 21 days before and that already exhibited strong bioluminescence signals, indicating an advanced stage of glioma growth. Local treatment: At day 21, osmotic minipumps delivering 50 ng IL-12Fc/day (or PBS) into the tumour were implanted into glioma bearing animals. After 28 days (day 49 after tumour injection) the empty pumps were explanted from surviving animals. Systemic treatment: At day 22, tumour bearing animals received 200 µg αCTLA-4 mouse IgG2b (9D9) or PBS i.p. Treatment was sustained with 100 µg αCTLA-4 at days 26, 29, 35 and 42 (Fig. 7). Neither IL-12Fc, nor anti-CTLA-4 alone conferred any significant survival advantage. Strikingly, the combination of local IL-12Fc administration directly into the tumour site in combination with systemic CTLA-4 blockade led to a full remission of the tumour (Fig. 8). 90 days after inoculation, histologic assessment of the brain tissue of surviving animals did not show any signs of demyelination or infiltrates. Local IL-12Fc administration in combination with systemic PD-1 blockade also led to a significant increase in surviving animals, the frequency was however lower than with systemic CTLA-4 blockade (Fig. 9). The above described combination therapy (Fig. 7) confers a significant survival advantage even in the case of intracranial growth of B16-F10 syngeneic murine melanoma cells (Fig. 10). This is not a perfect model for secondary brain tumours since it is skipping various steps of metastasis formation. Even in this more aggressive situation the combination treatment prolongs survival.

[0069] Preventive treatment of tumours in preclinical models may allow the study of immunological mechanisms and the interactions between tumour cells and tumour microenvironment. However, preventive therapy is of limited clinical relevance in the translation to treat cancer patients. We thus decided to choose an exceptionally late timepoint for intervention in a progressing and aggressive disease model. To closely mimic a clinical situation, we allowed the tumour to progress to a size that is highly likely to cause significant neurological symptoms in humans. Here, monotherapy with locally applied (intratumoural) IL-12 had a minimal albeit significant survival effect. We already observed a weak synergistic effect when we combined systemic IL-12 treatment with systemic CTLA-4 blockade. When local IL-12 infusion was combined with systemic CTLA-4 blockade, the anti-glioma effect was striking.

SEQUENCE LISTING

<110> Universitaet Zuerich

<120> Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy

<130> uz117wo

<160> 9

<170> PatentIn version 3.5

<210> 1

<211> 775

<212> PRT

<213> artificial

<220>

<223> fusion between human IL-12 and IgG4 Fc

<400> 1

Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu
1 5 10 15

Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val
20 25 30

Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu
35 40 45

Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln
50 55 60

Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys
65 70 75 80

Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val
85 90 95

Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp
100 105 110

Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe
115 120 125

Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp
130 135 140

Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg
145 150 155 160

EP 3 351 261 A1

	Gly	Ser	Ser	Asp	Pro	Gln	Gly	Val	Thr	Cys	Gly	Ala	Ala	Thr	Leu	Ser	
					165					170					175		
5	Ala	Glu	Arg	Val	Arg	Gly	Asp	Asn	Lys	Glu	Tyr	Glu	Tyr	Ser	Val	Glu	
				180					185					190			
10	Cys	Gln	Glu	Asp	Ser	Ala	Cys	Pro	Ala	Ala	Glu	Glu	Ser	Leu	Pro	Ile	
			195					200					205				
15	Glu	Val	Met	Val	Asp	Ala	Val	His	Lys	Leu	Lys	Tyr	Glu	Asn	Tyr	Thr	
		210					215					220					
20	Ser	Ser	Phe	Phe	Ile	Arg	Asp	Ile	Ile	Lys	Pro	Asp	Pro	Pro	Lys	Asn	
	225					230					235					240	
25	Leu	Gln	Leu	Lys	Pro	Leu	Lys	Asn	Ser	Arg	Gln	Val	Glu	Val	Ser	Trp	
					245					250					255		
30	Glu	Tyr	Pro	Asp	Thr	Trp	Ser	Thr	Pro	His	Ser	Tyr	Phe	Ser	Leu	Thr	
				260					265					270			
35	Phe	Cys	Val	Gln	Val	Gln	Gly	Lys	Ser	Lys	Arg	Glu	Lys	Lys	Asp	Arg	
			275					280					285				
40	Val	Phe	Thr	Asp	Lys	Thr	Ser	Ala	Thr	Val	Ile	Cys	Arg	Lys	Asn	Ala	
		290					295					300					
45	Ser	Ile	Ser	Val	Arg	Ala	Gln	Asp	Arg	Tyr	Tyr	Ser	Ser	Ser	Trp	Ser	
	305					310					315					320	
50	Glu	Trp	Ala	Ser	Val	Pro	Cys	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	
					325					330				335			
55	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Arg	Asn	Leu	Pro	Val	Ala	Thr	Pro	Asp	
			340						345					350			
60	Pro	Gly	Met	Phe	Pro	Cys	Leu	His	His	Ser	Gln	Asn	Leu	Leu	Arg	Ala	
			355					360					365				
65	Val	Ser	Asn	Met	Leu	Gln	Lys	Ala	Arg	Gln	Thr	Leu	Glu	Phe	Tyr	Pro	
		370					375					380					
70	Cys	Thr	Ser	Glu	Glu	Ile	Asp	His	Glu	Asp	Ile	Thr	Lys	Asp	Lys	Thr	
	385					390					395					400	
75	Ser	Thr	Val	Glu	Ala	Cys	Leu	Pro	Leu	Glu	Leu	Thr	Lys	Asn	Glu	Ser	
					405					410					415		

EP 3 351 261 A1

	Cys	Leu	Asn	Ser	Arg	Glu	Thr	Ser	Phe	Ile	Thr	Asn	Gly	Ser	Cys	Leu	
				420					425					430			
5	Ala	Ser	Arg	Lys	Thr	Ser	Phe	Met	Met	Ala	Leu	Cys	Leu	Ser	Ser	Ile	
				435				440					445				
10	Tyr	Glu	Asp	Leu	Lys	Met	Tyr	Gln	Val	Glu	Phe	Lys	Thr	Met	Asn	Ala	
		450					455					460					
15	Lys	Leu	Leu	Met	Asp	Pro	Lys	Arg	Gln	Ile	Phe	Leu	Asp	Gln	Asn	Met	
	465					470					475					480	
20	Leu	Ala	Val	Ile	Asp	Glu	Leu	Met	Gln	Ala	Leu	Asn	Phe	Asn	Ser	Glu	
					485					490					495		
25	Thr	Val	Pro	Gln	Lys	Ser	Ser	Leu	Glu	Glu	Pro	Asp	Phe	Tyr	Lys	Thr	
				500					505					510			
30	Lys	Ile	Lys	Leu	Cys	Ile	Leu	Leu	His	Ala	Phe	Arg	Ile	Arg	Ala	Val	
			515					520					525				
35	Thr	Ile	Asp	Arg	Val	Met	Ser	Tyr	Leu	Asn	Ala	Ser	Lys	Val	Asp	Lys	
		530					535					540					
40	Arg	Val	Glu	Ser	Lys	Tyr	Gly	Pro	Pro	Cys	Pro	Ser	Cys	Pro	Ala	Pro	
	545					550					555					560	
45	Glu	Phe	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	
				565						570					575		
50	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	
				580					585					590			
55	Asp	Val	Ser	Gln	Glu	Asp	Pro	Glu	Val	Gln	Phe	Asn	Trp	Tyr	Val	Asp	
			595					600					605				
60	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Phe	
		610					615					620					
65	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	
	625					630					635					640	
70	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Gly	Leu	
				645						650					655		
75	Pro	Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	
				660					665					670			

EP 3 351 261 A1

	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Pro	Glu	Glu	Met	Thr	Lys	
			675					680					685				
5	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	
		690					695					700					
10	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	
	705					710					715					720	
15	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	
					725					730					735		
20	Arg	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Glu	Gly	Asn	Val	Phe	Ser	
				740					745					750			
25	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	
			755					760					765				
30	Leu	Ser	Leu	Ser	Leu	Gly	Lys										
		770					775										
	<210>	2															
	<211>	781															
	<212>	PRT															
	<213>	Artificial Sequence															
	<220>																
	<223>	murine IL-12 IgG3 Fc fusion construct															
35	<400>	2															
40	Met	Cys	Pro	Gln	Lys	Leu	Thr	Ile	Ser	Trp	Phe	Ala	Ile	Val	Leu	Leu	
	1				5					10					15		
45	Val	Ser	Pro	Leu	Met	Ala	Met	Trp	Glu	Leu	Glu	Lys	Asp	Val	Tyr	Val	
				20					25					30			
50	Val	Glu	Val	Asp	Trp	Thr	Pro	Asp	Ala	Pro	Gly	Glu	Thr	Val	Asn	Leu	
			35					40					45				
55	Thr	Cys	Asp	Thr	Pro	Glu	Glu	Asp	Asp	Ile	Thr	Trp	Thr	Ser	Asp	Gln	
		50					55					60					
60	Arg	His	Gly	Val	Ile	Gly	Ser	Gly	Lys	Thr	Leu	Thr	Ile	Thr	Val	Lys	
	65					70					75					80	
65	Glu	Phe	Leu	Asp	Ala	Gly	Gln	Tyr	Thr	Cys	His	Lys	Gly	Gly	Glu	Thr	
					85					90					95		

EP 3 351 261 A1

	Leu	Ser	His	Ser	His	Leu	Leu	Leu	His	Lys	Lys	Glu	Asn	Gly	Ile	Trp	
				100					105					110			
5	Ser	Thr	Glu	Ile	Leu	Lys	Asn	Phe	Lys	Asn	Lys	Thr	Phe	Leu	Lys	Cys	
			115					120					125				
	Glu	Ala	Pro	Asn	Tyr	Ser	Gly	Arg	Phe	Thr	Cys	Ser	Trp	Leu	Val	Gln	
10		130					135					140					
	Arg	Asn	Met	Asp	Leu	Lys	Phe	Asn	Ile	Lys	Ser	Ser	Ser	Ser	Ser	Pro	
	145					150					155					160	
15	Asp	Ser	Arg	Ala	Val	Thr	Cys	Gly	Met	Ala	Ser	Leu	Ser	Ala	Glu	Lys	
					165					170					175		
	Val	Thr	Leu	Asp	Gln	Arg	Asp	Tyr	Glu	Lys	Tyr	Ser	Val	Ser	Cys	Gln	
20				180					185					190			
	Glu	Asp	Val	Thr	Cys	Pro	Thr	Ala	Glu	Glu	Thr	Leu	Pro	Ile	Glu	Leu	
25			195					200					205				
	Ala	Leu	Glu	Ala	Arg	Gln	Gln	Asn	Lys	Tyr	Glu	Asn	Tyr	Ser	Thr	Ser	
		210					215					220					
30	Phe	Phe	Ile	Arg	Asp	Ile	Ile	Lys	Pro	Asp	Pro	Pro	Lys	Asn	Leu	Gln	
	225					230					235					240	
	Met	Lys	Pro	Leu	Lys	Asn	Ser	Gln	Val	Glu	Val	Ser	Trp	Glu	Tyr	Pro	
35					245					250					255		
	Asp	Ser	Trp	Ser	Thr	Pro	His	Ser	Tyr	Phe	Ser	Leu	Lys	Phe	Phe	Val	
				260					265					270			
40	Arg	Ile	Gln	Arg	Lys	Lys	Glu	Lys	Met	Lys	Glu	Thr	Glu	Glu	Gly	Cys	
			275					280					285				
	Asn	Gln	Lys	Gly	Ala	Phe	Leu	Val	Glu	Lys	Thr	Ser	Thr	Glu	Val	Gln	
45		290					295					300					
	Cys	Lys	Gly	Gly	Asn	Val	Cys	Val	Gln	Ala	Gln	Asp	Arg	Tyr	Tyr	Asn	
50	305					310					315					320	
	Ser	Ser	Cys	Ser	Lys	Trp	Ala	Cys	Val	Pro	Cys	Arg	Val	Arg	Ser	Gly	
					325					330					335		
55	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Arg	Val	
				340					345					350			

EP 3 351 261 A1

	Ile	Pro	Val	Ser	Gly	Pro	Ala	Arg	Cys	Leu	Ser	Gln	Ser	Arg	Asn	Leu	
			355					360					365				
5	Leu	Lys	Thr	Thr	Asp	Asp	Met	Val	Lys	Thr	Ala	Arg	Glu	Lys	Leu	Lys	
		370					375					380					
10	His	Tyr	Ser	Cys	Thr	Ala	Glu	Asp	Ile	Asp	His	Glu	Asp	Ile	Thr	Arg	
	385					390					395					400	
15	Asp	Gln	Thr	Ser	Thr	Leu	Lys	Thr	Cys	Leu	Pro	Leu	Glu	Leu	His	Lys	
					405					410					415		
20	Asn	Glu	Ser	Cys	Leu	Ala	Thr	Arg	Glu	Thr	Ser	Ser	Thr	Thr	Arg	Gly	
				420					425					430			
25	Ser	Cys	Leu	Pro	Pro	Gln	Lys	Thr	Ser	Leu	Met	Met	Thr	Leu	Cys	Leu	
		435						440					445				
30	Gly	Ser	Ile	Tyr	Glu	Asp	Leu	Lys	Met	Tyr	Gln	Thr	Glu	Phe	Gln	Ala	
	450					455						460					
35	Ile	Asn	Ala	Ala	Leu	Gln	Asn	His	Asn	His	Gln	Gln	Ile	Ile	Leu	Asp	
	465					470					475					480	
40	Lys	Gly	Met	Leu	Val	Ala	Ile	Asp	Glu	Leu	Met	Gln	Ser	Leu	Asn	His	
					485					490					495		
45	Asn	Gly	Glu	Thr	Leu	Arg	Gln	Lys	Pro	Pro	Val	Gly	Glu	Ala	Asp	Pro	
				500					505					510			
50	Tyr	Arg	Val	Lys	Met	Lys	Leu	Cys	Ile	Leu	Leu	His	Ala	Phe	Ser	Thr	
			515					520					525				
55	Arg	Val	Val	Thr	Ile	Asn	Arg	Val	Met	Gly	Tyr	Leu	Ser	Ser	Ala	Leu	
	530					535						540					
60	Ile	Lys	Arg	Ile	Glu	Pro	Arg	Ile	Pro	Lys	Pro	Ser	Thr	Pro	Pro	Gly	
	545					550					555					560	
65	Ser	Ser	Cys	Pro	Pro	Gly	Asn	Ile	Leu	Gly	Gly	Pro	Ser	Val	Phe	Ile	
					565					570					575		
70	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Ala	Leu	Met	Ile	Ser	Leu	Thr	Pro	Lys	
				580					585					590			
75	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	Glu	Asp	Asp	Pro	Asp	Val	His	

EP 3 351 261 A1

595

600

605

5

Val Ser Trp Phe Val Asp Asn Lys Glu Val His Thr Ala Trp Thr Gln
610 615 620

10

Pro Arg Glu Ala Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Ala Leu
625 630 635 640

15

Pro Ile Gln His Gln Asp Trp Met Arg Gly Lys Glu Phe Lys Cys Lys
645 650 655

20

Val Asn Asn Lys Ala Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys
660 665 670

Pro Lys Gly Arg Ala Gln Thr Pro Gln Val Tyr Thr Ile Pro Pro Pro
675 680 685

Arg Glu Gln Met Ser Lys Lys Lys Val Ser Leu Thr Cys Leu Val Thr
690 695 700

25

Asn Phe Phe Ser Glu Ala Ile Ser Val Glu Trp Glu Arg Asn Gly Glu
705 710 715 720

30

Leu Glu Gln Asp Tyr Lys Asn Thr Pro Pro Ile Leu Asp Ser Asp Gly
725 730 735

Thr Tyr Phe Leu Tyr Ser Lys Leu Thr Val Asp Thr Asp Ser Trp Leu
740 745 750

35

Gln Gly Glu Ile Phe Thr Cys Ser Val Val His Glu Ala Leu His Asn
755 760 765

40

His His Thr Gln Lys Asn Leu Ser Arg Ser Pro Gly Lys
770 775 780

45

<210> 3
<211> 17
<212> DNA
<213> artificial

<220>
<223> PCR primer

50

<400> 3
acacacagcc tggacgc

17

55

<210> 4
<211> 20
<212> DNA
<213> artificial

<220>

<223> PCR primer

<400> 4

catttgaact ccttgcccct

20

<210> 5

<211> 219

<212> PRT

<213> homo sapiens

<400> 5

Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val Leu Leu
 1 5 10 15

Asp His Leu Ser Leu Ala Arg Asn Leu Pro Val Ala Thr Pro Asp Pro
 20 25 30

Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Arg Ala Val
 35 40 45

Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr Pro Cys
 50 55 60

Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys Thr Ser
 65 70 75 80

Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu Ser Cys
 85 90 95

Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys Leu Ala
 100 105 110

Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser Ile Tyr
 115 120 125

Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn Ala Lys
 130 135 140

Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn Met Leu
 145 150 155 160

Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser Glu Thr
 165 170 175

Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys Thr Lys
 180 185 190

EP 3 351 261 A1

Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala Val Thr
195 200 205

5 Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser
210 215

10 <210> 6
<211> 328
<212> PRT
<213> homo sapiens

<400> 6

15 Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu
1 5 10 15

20 Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val
20 25 30

25 Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu
35 40 45

Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln
50 55 60

30 Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys
65 70 75 80

35 Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val
85 90 95

Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp
100 105 110

40 Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe
115 120 125

45 Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp
130 135 140

50 Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg
145 150 155 160

Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser
165 170 175

55 Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu
180 185 190

EP 3 351 261 A1

Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile
195 200 205

5 Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr
210 215 220

10 Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn
225 230 235 240

Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp
245 250 255

15 Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr
260 265 270

20 Phe Cys Val Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg
275 280 285

Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala
290 295 300

25 Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser
305 310 315 320

30 Glu Trp Ala Ser Val Pro Cys Ser
325

35 <210> 7
<211> 2328
<212> DNA
<213> artificial

40 <220>
<223> expression construct, coding sequence for IL-12 IgG4 Fc fusion
protein

45 <400> 7
atgtgtcacc agcagttggt catctcttgg ttttccctgg tttttctggc atctcccctc 60
gtggccatat gggaactgaa gaaagatggt tatgtcgtag aattggattg gtatccggat 120
gcccctggag aaatggtggt cctcacctgt gacacccctg aagaagatgg tatcacctgg 180
accttggaacc agagcagtga ggtcttaggc tctggcaaaa ccctgaccat ccaagtcaaa 240
gagtttggag atgctggcca gtacacctgt cacaaaggag gcgaggttct aagccattcg 300
ctcctgctgc ttcacaaaaa ggaagatgga atttgggtcca ctgatatttt aaaggaccag 360
aaagaaccca aaaataagac ctttctaaga tgcgaggcca agaattattc tggacgtttc 420
acctgctggt ggctgacgac aatcagtact gatttgacat tcagtgtcaa aagcagcaga 480
55 ggctcttctg acccccaagg ggtgacgtgc ggagctgcta cactctctgc agagagagtc 540

EP 3 351 261 A1

	agaggggaca acaaggagta tgagtactca gtggagtgcc aggaggacag tgcctgcccc	600
	gctgctgagg agagtctgcc cattgaggtc atggtggatg ccgttcacaa gctcaagtat	660
5	gaaaactaca ccagcagctt cttcatcagg gacatcatca aacctgacct acccaagaac	720
	ttgcagctga agccattaaa gaattctcgg caggtggagg tcagctggga gtaccctgac	780
	acctggagta ctccacattc ctacttctcc ctgacattct gcgttcaggt ccagggcaag	840
10	agcaagagag aaaagaaaga tagagtcttc acggacaaga cctcagccac ggtcatctgc	900
	cgcaaaaatg ccagcattag cgtgcgggcc caggaccgct actatagctc atcttgagc	960
	gaatgggcat ctgtgccctg cagtggaggc ggtggctcgg gcggtggtgg gtcgggtggc	1020
15	ggcggatcca gaaacctccc cgtggccact ccagaccag gaatgttccc atgccttcac	1080
	cactcccaaa acctgctgag ggccgtcagc aacatgctcc agaaggccag acaactcta	1140
	gaattttacc cttgcacttc tgaagagatt gatcatgaag atatcacaaa agataaaacc	1200
20	agcacagtgg aggcctgttt accattggaa ttaaccaaga atgagagttg cctaaattcc	1260
	agagagacct ctttcataac taatgggagt tgcctggcct ccagaaagac ctcttttatg	1320
	atggccctgt gccttagtag tatttatgaa gacttgaaga tgtaccaggt ggagttcaag	1380
25	accatgaatg caaagcttct gatggatcct aagaggcaga tctttctaga tcaaaacatg	1440
	ctggcagtta ttgatgagct gatgcaggcc ctgaatttca acagtgagac tgtgccacaa	1500
30	aaatcctccc ttgaagaacc ggatttttat aaaactaaaa tcaagctctg catacttctt	1560
	catgctttca gaattcgggc agtgactatt gatagagtga tgagctatct gaatgcttcc	1620
	aaggtggaca agagagttga gtccaaatat ggtcccccat gcccatcatg cccagcacct	1680
35	gagttcctgg ggggaccatc agtcttcctg ttccccccaa aaccaagga cactctcatg	1740
	atctcccga cccctgaggt cacgtgcgtg gtggtggacg tgagccagga agaccccgag	1800
	gtccagttca actggtacgt ggatggcgtg gaggtgcata atgccaagac aaagccgcgg	1860
40	gaggagcagt tcaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac	1920
	tggctgaacg gcaaggagta caagtgcaag gtctccaaca aaggcctccc gtcctccatc	1980
45	gagaaaacca tctccaaagc caaagggcag ccccgagagc cacaggtgta caccctgccc	2040
	ccatccccgg aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc	2100
	taccccgagc acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag	2160
50	accacgcctc ccgtgctgga ctccgacggc tccttcttcc tctacagcag gctaaccgtg	2220
	gacaagagca ggtggcagga ggggaatgtc ttctcatgct ccgtgatgca tgaggctctg	2280
	cacaaccact acacacagaa gagcctctcc ctgtctctgg gtaaatga	2328

55

<210> 8

EP 3 351 261 A1

<211> 10994
<212> DNA
<213> artificial

<220>

<223> plasmid vector encoding Fc tag (murine)

<400> 8

5	ctcgcagcaa agcaagatgt gtcctcagaa gctaaccatc tcctggtttg ccatcgtttt	60
10	gctgggtgtct ccactcatgg ccatgtggga gctggagaag cttatcaaga gaatcgagcc	120
	tagaataccc aagcccagta cccccccagg ttcttcatgc ccacctggta acatcttggg	180
	tggaccatcc gtcttcatct tccccccaaa gcccaaggat gcactcatga tctccctaac	240
15	ccccaaaggtt acgtgtgtgg tgggtggatgt gagcgaggat gaccagatg tccatgtcag	300
	ctggtttgtg gacaacaaag aagtacacac agcctggacg cagccccgtg aagctcagta	360
	caacagtacc ttccgagtgg tcagtgccct ccccatccag caccaggact ggatgagggg	420
20	caaggagttc aaatgcaagg tcaacaacaa agccctccca gcccccatcg agagaaccat	480
	ctcaaaaccc aaaggaagag ccagacacac tcaagtatac accatacccc cacctcgtga	540
25	acaaatgtcc aagaagaagg ttagtctgac ctgcctgggc accaacttct tctctgaagc	600
	catcagtgtg gagtgggaaa ggaacggaga actggagcag gattacaaga aactccacc	660
	catcctggac tcggatggga cctacttcct ctacagcaag ctactgtgg atacagacag	720
30	ttggttgcaa ggagaaatth ttacctgctc cgtgggtgcat gaggctctcc ataaccacca	780
	cacacagaag aacctgtctc gctcccctgg taaatgagaa cagcatctag cggccgctcg	840
	aggccggcaa ggccggatcc agacatgata agatacattg atgagtttgg acaaaccaca	900
35	actagaatgc agtgaaaaaa atgctttatt tgtgaaatth gtgatgctat tgctttatth	960
	gtaaccatta taagctgcaa taaacaagtt aacaacaaca attgcattca ttttatgtth	1020
	caggttcagg gggaggtgtg ggaggtttth taaagcaagt aaaacctcta caaatgtggt	1080
40	atggctgatt atgatccggc tgcctcgcg cgttcgggtga tgacggtgaa aacctctgac	1140
	acatgcagct cccggagacg gtcacagctt gtctgtaagc ggatgccggg agcagacaag	1200
	cccgctcaggc gtcagcgggt gttggcgggt gtcggggcgc agccatgagg tcgactctag	1260
45	aggatcgatg ccccgccccg gacgaactaa acctgactac gacatctctg ccccttcttc	1320
	gcggggcagt gcatgtaatc ccttcagttg gttggtacaa cttgccaaact gggccctgth	1380
	ccacatgtga cacggggggg gaccaaacac aaaggggttc tctgactgta gttgacatcc	1440
50	ttataaatgg atgtgcacat ttgccaaacac tgagtggctt tcatcctgga gcagactthg	1500
	cagtctgtgg actgcaacac aacattgcct ttatgtgtaa ctcttggtg aagctcttac	1560
55	accaatgctg ggggacatgt acctcccagg gggccaggaa gactacggga ggctacacca	1620
	acgtcaatca gaggggcctg tgtagctacc gataagcggg ccctcaagag ggcattagca	1680

EP 3 351 261 A1

	atagtgttta taaggccccc ttgttaaccc taaacgggta gcatatgctt cccgggtagt	1740
	agtatatact atccagacta accctaattc aatagcatat gttaccaaac gggaagcata	1800
5	tgctatcgaa ttaggggttag taaaagggtc ctaaggaaca gcgatatctc ccaccccatg	1860
	agctgtcacg gttttattta catgggggtca ggattccacg agggtagtga accatttttag	1920
	tcacaagggc agtggctgaa gatcaaggag cgggcagtga actctcctga atcttcgcct	1980
10	gcttcttcat tctccttcgt ttagctaata gaataactgc tgagtttgtga acagtaaggt	2040
	gtatgtgagg tgctcgaaaa caagggttca ggtgacgccc ccagaataaa atttggacgg	2100
15	ggggttcagt ggtggcattg tgctatgaca ccaatataac cctcacaaac cccttgggca	2160
	ataaatacta gtgtaggaat gaaacattct gaatatcttt aacaatagaa atccatgggg	2220
	tggggacaag ccgtaaagac tggatgtcca tctcacacga atttatggct atgggcaaca	2280
20	cataatccta gtgcaatatg atactgggggt tattaagatg tgtcccaggc agggaccaag	2340
	acaggtgaac catgtttgtta cactctatctt gtaacaagggt gaaagagagt ggacgccgac	2400
	agcagcggac tccactgggt gtctctaaca cccccgaaaa ttaaacgggg ctccacgcca	2460
25	atggggccca taaacaaaga caagtggcca ctcttttttt tgaaattgtg gagtgggggc	2520
	acgcgtcagc ccccacacgc cgccctgcgg ttttggactg taaaataagg gtgtaataac	2580
	ttggctgatt gtaaccccg ctaaccactgc ggtcaaacca cttgccaca aaaccactaa	2640
30	tggcaccocg gggaatacct gcataagtag gtgggcgggc caagataggg gcgcgattgc	2700
	tgcgatctgg aggacaaatt acacacactt gcgcctgagc gccaaagcaca gggttgttgg	2760
35	tcctcatatt cacgaggtcg ctgagagcac ggtgggctaa tgttgccatg ggtagcatat	2820
	actacccaaa tatctggata gcatatgcta tcctaatacta tatctgggta gcataggcta	2880
	tcctaatacta tatctgggta gcatatgcta tcctaatacta tatctgggta gtatatgcta	2940
40	tcctaattta tatctgggta gcataggcta tcctaatacta tatctgggta gcatatgcta	3000
	tcctaatacta tatctgggta gtatatgcta tcctaatactg tatccgggta gcatatgcta	3060
	tcctaataga gattagggta gtatatgcta tcctaattta tatctgggta gcatatacta	3120
45	cccaaataatc tggatagcat atgctatcct aatctatatc tgggtagcat atgctatcct	3180
	aatctatatc tgggtagcat aggctatcct aatctatatc tgggtagcat atgctatcct	3240
	aatctatatc tgggtagtat atgctatcct aatttatatc tgggtagcat aggctatcct	3300
50	aatctatatc tgggtagcat atgctatcct aatctatatc tgggtagtat atgctatcct	3360
	aatctgtatc cgggtagcat atgctatcct catgcatata cagtcagcat atgataccca	3420
55	gtagtagagt gggagtgcta tcctttgcat atgccgccac ctcccaaggg ggcgtgaatt	3480
	ttcgctgctt gtccctttcc tgctgggtgc tccattctt aggtgaattt aaggaggcca	3540

EP 3 351 261 A1

	ggctaaagcc gtcgcatgtc tgattgctca ccaggtaaata gtcgctaatag ttttccaacg	3600
	cgagaaggtg ttgagcgcgg agctgagtga cgtgacaaca tgggtatgcc caattgcccc	3660
5	atgttgggag gacgaaaatg gtgacaagac agatggccag aaatacacca acagcacgca	3720
	tgatgtctac tggggattta ttcttttagtg cgggggaata cacggctttt aatacgattg	3780
	agggcgtctc ctaacaagtt acatcactcc tgcccttctt caccctcatc tccatcacct	3840
10	ccttcatctc cgtcatctcc gtcacacccc tccgcggcag ccccttccac cataggtgga	3900
	aaccaggggag gcaaactctac tccatcgtca aagctgcaca cagtcaccct gatattgcag	3960
	gtaggagcgg gctttgtcat aacaaggtcc ttaatcgcat ccttcaaac ctgagcaaat	4020
15	atatgagttt gtaaaaagac catgaaataa cagacaatgg actcccttag cgggcccagg	4080
	tgtgggccgg gtccaggggc cattccaaag gggagacgac tcaatgggtg aagacgacat	4140
	tgtggaatag caagggcagt tcctcgcctt aggttgtaaa gggaggtctt actacctcca	4200
20	tatacgaaca caccggcgac ccaagttcct tcgtcggtag tcctttctac gtgactccta	4260
	gccaggagag ctcttaaac ttctgcaatg ttctcaaatt tcgggttgga acctccttga	4320
	ccacgatgct ttccaaacca cctcctttt ttgcgcctgc ctccatcacc ctgaccccg	4380
25	ggtccagtgc ttgggccttc tcctgggtca tctgcggggc cctgctctat cgctcccg	4440
	ggcacgtcag gctcaccatc tgggccacct tcttggtggt attcaaaata atcggttcc	4500
	cctacagggg ggaaaaatgg ccttctacct ggagggggcc tgcgcggtgg agacccgat	4560
30	gatgatgact gactactggg actcctgggc ctcttttctc cacgtccacg acctctcccc	4620
	ctggctcttt cactacttcc cccctgggt ctctcacgtc ctctaccccg gcggcctcca	4680
35	ctacctctc gaccccgcc tccactacct cctcgacccc ggctccact gcctcctga	4740
	ccccggcctc cactcctgc tcctgcccct cctgctcctg cccctcctcc tgctcctgcc	4800
	cctcctgccc ctctgctcc tgcccctcct gccctcctg ctctgcccc tcctgcccct	4860
40	cctgctcctg cccctcctgc cctcctcct gctcctgccc ctctgcccc tcctcctgct	4920
	cctgcccctc ctgcccctcc tgctcctgcc cctcctgccc ctctgctcc tgcccctcct	4980
	gcccctcctg ctctgcccc tcctgctcct gccctcctg ctctgcccc tcctgctcct	5040
45	gcccctcctg cccctcctgc cctcctcct gctcctgccc ctctgctcc tgcccctcct	5100
	gcccctcctg cccctcctgc tcctgcccct cctcctgctc ctgcccctcc tgcccctcct	5160
	gcccctcctc ctgctcctgc cctcctgccc cctcctcctg ctctgcccc tcctcctgct	5220
50	cctgcccctc ctgcccctcc tgcccctcct cctgctcctg cccctcctgc cctcctcct	5280
	gctcctgccc ctctcctgc tcctgcccct cctgcccctc ctgcccctcc tcctgctcct	5340
55	gcccctcctc ctgctcctgc cctcctgccc cctcctgccc ctctgcccc tcctcctgct	5400
	cctgcccctc ctctgctcc tgcccctcct gctcctgccc ctccgctcc tgctcctgct	5460

EP 3 351 261 A1

	cctgttccac cgtgggtccc tttgcagcca atgcaacttg gacgtttttg ggggtctccgg	5520
	acaccatctc tatgtcttgg ccctgatcct gagccgcccg ggggtcctgg tcttccgcct	5580
5	cctcgtcctc gtcctcttcc ccgtcctcgt ccatggttat cccccctct tctttgaggt	5640
	ccactgccgc cggagccttc tgggtccagat gtgtctccct tctctcctag gccatttcca	5700
	ggtcctgtac ctggcccctc gtcagacatg attcacacta aaagagatca atagacatct	5760
10	ttattagacg acgctcagtg aatacagggg gtgcagactc ctgccccctc caacagcccc	5820
	cccaccctca tccccctcat ggctcgtctc agacagatcc aggtctgaaa attccccatc	5880
15	ctccgaacca tctcgtcct catcaccaat tactcgcagc ccggaaaact cccgctgaac	5940
	atcctcaaga tttgcgtcct gagcctcaag ccaggcctca aattcctcgt cccccctttt	6000
	gctggacggg agggatgggg attctcggga cccctcctct tctcttcaa ggtcaccaga	6060
20	cagagatgct actggggcaa cgggaagaaa gctgggtgcg gcctgtgagg atcagcttat	6120
	cgatgataag ctgtcaaaca tgagaattct tgaagacgaa agggcctcgt gatacgccta	6180
	tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggtgg cacttttcgg	6240
25	ggaaatgtgc gcggaacccc tatttgttta ttttctaaa tacattcaaa tatgtatccg	6300
	ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa gagtatgagt	6360
	attcaacatt tccgtgtgc ccttattccc ttttttgcgg cattttgcct tctgttttt	6420
30	gctcaccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg tgcacgagtg	6480
	ggttacatcg aactggatct caacagcggg aagatccttg agagttttcg ccccgagaa	6540
35	cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt atcccggtgt	6600
	gacgccgggc aagagcaact cggctcgcgc atacactatt ctcagaatga cttgggttag	6660
	tactcaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga attatgcagt	6720
40	gctgccataa ccatgagtga taacactgcg gccaaacttac ttctgacaac gatcggagga	6780
	ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg ccttgatcgt	6840
	tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac gatgcctgca	6900
45	gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct agcttcccg	6960
	caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct gcgctcggcc	7020
	cttccggctg gctggtttat tgctgataaa tctggagccg gtgagcgtgg gtctcgcgg	7080
50	atcattgcag cactggggcc agatggtaag ccctcccgta tcgtagttaa ctacacgacg	7140
	gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg tgccctactg	7200
55	attaagcatt ggtaactgtc agaccaagtt tactcatata tacttttagat tgatttaaaa	7260
	cttcattttt aattttaaag gatctaggtg aagatccttt ttgataatct catgaccaa	7320

EP 3 351 261 A1

	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	gatcaaagga	7380
	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	aaaaccaccg	7440
5	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	ctctttttcc	gaaggtaact	7500
	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	gttaggccac	7560
	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	tgctaatacct	gttaccagtg	7620
10	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	actcaagacg	atagttaccg	7680
	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	cttgagcgca	7740
	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	cacgcttccc	7800
15	gaagggagaa	aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	agagcgcacg	7860
	agggagcttc	cagggggaaa	cgcctggtat	ctttatagtc	ctgtcggggt	tcgccacctc	7920
	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	gaaaaacgcc	7980
20	agcaacgcgg	ccttttttacg	gttcctggcc	ttttgctggc	cttgaagctg	tccctgatgg	8040
	tcgtcatcta	cctgcctgga	cagcatggcc	tgcaacgcgg	gcatcccgat	gccgccggaa	8100
25	gcgagaagaa	tcataatggg	gaaggccatc	cagcctcgcg	tcgcgaacgc	cagcaagacg	8160
	tagcccagcg	cgtcggcccc	gagatgcgcc	gcgtgcggct	gctggagatg	gcggacgcga	8220
	tggatatgtt	ctgccaaagg	ttggtttgcg	cattcacagt	tctccgcaag	aattgattgg	8280
30	ctccaattct	tggagtggtg	aatccgtag	cgaggtgccg	ccctgcttca	tccccgtggc	8340
	ccgttgctcg	cgtttgctgg	cggtgtcccc	ggaagaaata	tatttgcatg	tctttagttc	8400
	tatgatgaca	caaaccccg	ccagcgtctt	gtcattggcg	aattcgaaca	cgcagatgca	8460
35	gtcggggcgg	cgcgggtccga	ggccacttc	gcatattaag	gtgacgcgtg	tggcctcgaa	8520
	caccgagcga	ccctgcagcg	acccgcttaa	cagcgtcaac	agcgtgccgc	agatcccggg	8580
	gggcaatgag	atatgaaaaa	gcctgaactc	accgcgacgt	ctgtcgagaa	gtttctgatc	8640
40	gaaaagtctg	acagcgtctc	cgacctgatg	cagctctcgg	agggcgaaga	atctcgtgct	8700
	ttcagcttcg	atgtaggagg	gcgtggatat	gtcctgcggg	taaatagctg	cgccgatgg	8760
	ttctacaaag	atcgttatgt	ttatcggcac	tttgcatcgg	ccgcgctccc	gattccggaa	8820
45	gtgcttgaca	ttggggaatt	cagcgagagc	ctgacctatt	gcatctcccg	ccgtgcacag	8880
	ggtgtcacgt	tgcaagacct	gcctgaaacc	gaactgcccg	ctgttctgca	gccggtcgcg	8940
50	gaggccatgg	atgcgatcgc	tgccggccgat	cttagccaga	cgagcggggt	cggcccattc	9000
	ggaccgcaag	gaatcgggtca	atacactaca	tggcgtgatt	tcatatgcgc	gattgctgat	9060
	ccccatgtgt	atcactggca	aactgtgatg	gacgacaccg	tcagtgcgtc	cgtcgcgcag	9120
55	gctctcgatg	agctgatgct	ttggggccgag	gactgccccg	aagtccggca	cctcgtgcac	9180
	gcggatttctg	gtccaacaaa	tgtcctgacg	gacaatggcc	gcataacagc	ggtcattgac	9240

EP 3 351 261 A1

5 tggagcgcgagg cgatgttcggtt ggattcccaa tacgaggtcg ccaacatctt cttctggagg 9300
 ccgtgggttg cttgtatgga gcagcagacg cgctacttcg agcggaggca tccggagctt 9360
 10 gcaggatcgc cgcggctccg ggcgtatatg ctccgcattg gtcttgacca actctatcag 9420
 agcttggttg acggcaattt cgatgatgca gcttgggcgc agggtcgatg cgacgcaatc 9480
 gtccgatccg gagccgggac tgtcgggcgt acacaaatcg cccgcagaag cgcggccgtc 9540
 15 tggaccgatg gctgtgtaga agtactcgcc gatagtggaa accgacgccc cagcactcgt 9600
 ccggatcggg agatggggga ggctaactga aacacggaag gagacaatac cggaaggaac 9660
 ccgcgctatg acggcaataa aaagacagaa taaaacgcac ggggtgttggg tcgtttgttc 9720
 ataaacgcgg ggttcggtcc cagggtcggc actctgtcga taccaccacg agaccacatt 9780
 20 ggggccaata cgcgcgctt tcttcctttt cccaccccca cccccaagt tcgggtgaag 9840
 gccagggct cgcagccaac gtcggggcgg caggccctgc catagccact ggccccgtgg 9900
 gttagggacg gggccccca tggggaatgg tttatggttc gtgggggtta ttattttggg 9960
 cgttgcgtgg ggtcaggtcc acgactggac tgagcagaca gaccatggt ttttgatgg 10020
 25 cctgggcatg gaccgcatgt actggcgcga cacgaacacc gggcgtctgt ggctgccaaa 10080
 ccccccgac ccccaaaaac caccgcgcgg atttctggcg tgccaagcta gtcgaccaat 10140
 tctcatgttt gacagcttat catcgcagat ccgggcaacg ttgttgccat tgctgcaggc 10200
 30 gcagaactgg taggtatgga agatctatac attgaatcaa tattggcaat tagccatatt 10260
 agtcattggt tatatagcat aaatcaatat tggctattgg ccattgcata cgttgtatct 10320
 atatcataat atgtacattt atattggctc atgtccaata tgaccgcat gttgacattg 10380
 35 attattgact agttattaat agtaatcaat tacggggtca ttagttcata gccatataat 10440
 ggagttccgc gttacataac ttacggtaaa tggccgcct ggctgaccgc ccaacgaccc 10500
 ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 10560
 40 ttgacgtcaa tgggtggagt atttacggt aactgcccac ttggcagtac atcaagtgt 10620
 tcatatgcc agtccgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 10680
 45 tgcccagtac atgaccttac gggactttcc tacttggcag tacatctacg tattagtcac 10740
 cgctattacc atggtgatgc ggttttgcca gtacaccaat gggcgtggat agcggtttga 10800
 ctacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt tttggacca 10860
 50 aaatcaacgg gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc aaatgggcgg 10920
 taggcgtgta cgggtgggag tctatataag cagagctcgt ttagtgaacc gtcagatctc 10980
 tagaagctgg gtac 10994

<210> 9

EP 3 351 261 A1

<211> 12539
<212> DNA
<213> artificial

<220>

<223> plasmid vector encoding Fc-tag IL-12 fusion construct

<400> 9

```

gtacctcgca gcaaagcaag atgtgtcctc agaagctaac catctcctgg ttgccatcg      60
10  ttttgctggg gtctccactc atggccatgt gggagctgga gaaagacgtt tatgtttag      120
    aggtggactg gactcccgat gccctggag aaacagtga cctcacctgt gacacgcctg      180
    aagaagatga catcacctgg acctcagacc agagacatgg agtcataggc tctggaaaaga      240
15  ccctgaccat cactgtcaaa gagtttctag atgctggcca gtacacctgc cacaaaggag      300
    gcgagactct gagccactca catctgctgc tccacaagaa ggaaaatgga atttggcca      360
    ctgaaatddd aaaaaattdc aaaaacaaga ctttcctgaa gtgtgaagca ccaaattact      420
20  ccggacgggt cactgtctca tggctggtgc aaagaaacat ggacttgaag ttcaacatca      480
    agagcagtag cagttcccct gactctcggg cagtgcacatg tggaatggcg tctctgtctg      540
    cagagaaggt cacactggac caaagggact atgagaagta ttcagtgtcc tgccaggagg      600
25  atgtcacctg cccaactgcc gaggagaccc tgcccattga actggcggtg gaagcacggc      660
    agcagaataa atatgagaac tacagcacca gcttcttcat caggacatc atcaaaccag      720
    acccgcccaa gaacttgagc atgaagcctt tgaagaactc acaggtggag gtcagctggg      780
30  agtaccctga ctctggagc actccccatt cctacttctc cctcaagttc tttgttcgaa      840
    tccagcgcaa gaaagaaaag atgaaggaga cagaggaggg gtgtaaccag aaaggtgcgt      900
35  tcctcgtaga gaagacatct accgaagtcc aatgcaaagg cgggaatgtc tgcgtgcaag      960
    ctccagatcg ctattacaat tcctcgtaga gcaagtgggc atgtgttccc tgcagggtcc      1020
    gatccggagg cgggtggctcg ggcggtggtg ggtcgggtgg cggcggatcc agggtcattc      1080
40  cagtctctgg acctgccagg tgtcttagcc agtcccgaaa cctgctgaag accacagatg      1140
    acatggtgaa gacggccaga gaaaaactga aacattattc ctgcactgct gaagacatcg      1200
    atcatgaaga catcacacgg gaccaaacca gcacattgaa gacctgttta ccaactggaac      1260
45  tacacaagaa cgagagttgc ctggctacta gagagacttc ttccacaaca agaggagct      1320
    gcctgccccc acagaagacg tctttgatga tgacctgtg ccttggtagc atctatgagg      1380
    acttgaagat gtaccagaca gagttccagg ccatcaacgc agcacttcag aatcacaacc      1440
50  atcagcagat cattctagac aagggcattg tgggtggccat cgatgagctg atgcagtctc      1500
    tgaatcataa tggcgagact ctgcgccaga aacctcctgt gggagaagca gacccttaca      1560
55  gagtgaataa gaagctctgc atcctgcttc acgccttcag caccgcgctc gtgaccatca      1620
    acagggtgat gggctatctg agctccgcct tgatcaagag aatcgagcct agaataccca      1680

```

EP 3 351 261 A1

	agcccagtag	ccccccaggt	tcttcatgcc	cacctggtaa	catcttgggt	ggaccatccg	1740
	tcttcatctt	ccccccaaag	cccaaggatg	cactcatgat	ctccctaacc	cccaaggtta	1800
5	cgtgtgtggt	ggtggatgtg	agcgaggatg	accagatgt	ccatgtcagc	tggtttgtgg	1860
	acaacaaaga	agtacacaca	gcctggacgc	agccccgtga	agctcagtag	aacagtagct	1920
	tccgagtggg	cagtgccttc	cccatccagc	accaggactg	gatgaggggc	aaggagttca	1980
10	aatgcaagg	caacaacaaa	gccctcccag	cccccatcga	gagaaccatc	tcaaaaccca	2040
	aaggaagagc	ccagacacct	caagtataca	ccatacccc	acctcgtgaa	caaagtcca	2100
15	agaagaagg	tagtctgacc	tgcttgggtc	ccaacttctt	ctctgaagcc	atcagtgtgg	2160
	agtgggaaag	gaacggagaa	ctggagcagg	attacaagaa	cactccaccc	atcctggact	2220
	cggatgggac	ctacttcctc	tacagcaagc	tactgtgga	tacagacagt	tggttgcaag	2280
20	gagaaatttt	tacctgctcc	gtggtgcatg	aggctctcca	taaccaccac	acacagaaga	2340
	acctgtctcg	ctccccctgg	aaatgagaac	agcatctagc	ggccgctcga	ggccggcaag	2400
	gccggatcca	gacatgataa	gatacattga	tgagtttgga	caaaccacaa	ctagaatgca	2460
25	gtgaaaaaaa	tgctttattt	gtgaaatttg	tgatgctatt	gctttatttg	taaccattat	2520
	aagctgcaat	aaacaagtta	acaacaacaa	ttgcattcat	tttatgtttc	aggttcaggg	2580
	ggaggtgtgg	gaggtttttt	aaagcaagta	aaacctctac	aaatgtggta	tggctgatta	2640
30	tgatccggct	gcctcgcgcg	tttcgggtgat	gacggtgaaa	acctctgaca	catgcagctc	2700
	ccggagacgg	tcacagcttg	tctgtaagcg	gatgccggga	gcagacaagc	ccgtcaggcg	2760
35	tcagcgggtg	ttggcgggtg	tcggggcgca	gccatgaggt	cgactctaga	ggatcgatgc	2820
	cccgccccgg	acgaactaaa	cctgactacg	acatctctgc	cccttcttcg	cggggcagtg	2880
	catgtaatcc	cttcagttgg	ttggtacaac	ttgccaaactg	ggccctgttc	cacatgtgac	2940
40	acgggggggg	accaaacaca	aaggggttct	ctgactgtag	ttgacatcct	tataaatgga	3000
	tgtgcacatt	tgccaacact	gagtggcttt	catcctggag	cagactttgc	agtctgtgga	3060
	ctgcaacaca	acattgcctt	tatgtgtaac	tcttggctga	agctcttaca	ccaatgctgg	3120
45	gggacatgta	cctcccaggg	gccaggaag	actacgggag	gctacaccaa	cgtcaatcag	3180
	aggggcctgt	gtagctaccg	ataagcggac	cctcaagagg	gcattagcaa	tagtgtttat	3240
	aaggccccct	tggttaaccct	aaacgggtag	catatgcttc	ccgggtagta	gtatatacta	3300
50	tccagactaa	ccctaattca	atagcatatg	ttacccaacg	ggaagcatat	gctatcgaat	3360
	tagggtagt	aaaagggtcc	taaggaacag	cgatatctcc	caccccatga	gctgtcacgg	3420
55	ttttatttac	atgggggtcag	gattccacga	gggtagtga	ccattttagt	cacaagggca	3480
	gtggctgaag	atcaaggagc	gggcagtga	ctctcctgaa	tcttcgcctg	cttcttcatt	3540

EP 3 351 261 A1

	ctccttcggt tagctaataag aataactgct gagttgtgaa cagtaaggtg tatgtgaggt	3600
	gctcgaataac aaggtttcag gtgacgcccc cagaataaaa tttggacggg gggttcagtg	3660
5	gtggcattgt gctatgacac caatataacc ctcacaaaacc ccttgggcaa taaatactag	3720
	tgtaggaatg aaacattctg aatatcttta acaatagaaa tccatggggg ggggacaagc	3780
	cgtaaagact ggatgtccat ctcacacgaa tttatggcta tgggcaacac ataactctag	3840
10	tgcaatatga tactgggggtt attaagatgt gtcccaggca gggaccaaga caggtgaacc	3900
	atgttggttac actctatttg taacaagggg aaagagagtg gacgccgaca gcagcggact	3960
	ccactgggtg tctctaaccac ccccgaaaat taaacggggc tccacgcca tggggcccat	4020
15	aaacaaagac aagtggccac tctttttttt gaaattgtgg agtgggggca cgcgtcagcc	4080
	cccacacgcc gccctgcggg tttggactgt aaaataaggg tgtaataact tggctgattg	4140
	taacccccgt aaccactgcg gtcaaaccac ttgccacaaa aaccactaat ggcacccccg	4200
20	ggaataacct cataagtagg tgggcggggc aagatagggg cgcgattgct gcgatctgga	4260
	ggacaaatta cacacacttg cgcctgagcg ccaagcacag ggttggttgg cctcatattc	4320
	acgaggtcgc tgagagcacg gtgggctaata gttgccatgg gtagcatata ctacccaaat	4380
25	atctggatag catatgctat cctaactctat atctgggtag cataggctat cctaactctat	4440
	atctgggtag catatgctat cctaactctat atctgggtag tatatgctat cctaatttat	4500
30	atctgggtag cataggctat cctaactctat atctgggtag catatgctat cctaactctat	4560
	atctgggtag tatatgctat cctaactctg atccgggtag catatgctat cctaataagag	4620
	attagggtag tatatgctat cctaatttat atctgggtag catatactac ccaaatatct	4680
35	ggatagcata tgctatccta atctatatct gggtagcata tgctatccta atctatatct	4740
	gggtagcata ggctatccta atctatatct gggtagcata tgctatccta atctatatct	4800
	gggtagcata tgctatccta atctatatct gggtagcata ggctatccta atctatatct	4860
40	gggtagcata tgctatccta atctatatct gggtagcata tgctatccta atctgtatcc	4920
	gggtagcata tgctatcctc atgcatatac agtcagcata tgatacccag tagtagagtg	4980
	ggagtgcctat cctttgcata tgccgccacc tcccaagggg gcgtgaattt tcgctgcttg	5040
45	tccttttcct gctgggtgct ccattctta ggtgaattta aggaggccag gctaaagccg	5100
	tcgcatgtct gattgctcac caggtaaatg tcgctaattg tttccaacgc gagaagggtg	5160
	tgagcgcgga gctgagtgac gtgacaacat gggtagcacc aattgcccc tgggtggagg	5220
50	acgaaaatgg tgacaagaca gatggccaga aatacaccaa cagcacgcat gatgtctact	5280
	ggggatttat tctttagtgc gggggaatac acggctttta atacgattga gggcgtctcc	5340
55	taacaagtta catcactcct gcccttcctc accctcatct ccatcacctc cttcatctcc	5400
	gtcatctccg tcatcacctc ccgcggcagc cccttcacac ataggtggaa accaggggagg	5460

EP 3 351 261 A1

	caaactact	ccatcgtcaa	agctgcacac	agtcaccctg	atattgcagg	taggagcggg	5520
	ctttgtcata	acaaggtcct	taatcgcatc	cttcaaaacc	tcagcaaata	tatgagtttg	5580
5	taaaaagacc	atgaaataac	agacaatgga	ctcccttagc	gggccagggt	gtgggccggg	5640
	tccagggggc	attccaaagg	ggagacgact	caatgggtgta	agacgacatt	gtggaatagc	5700
	aagggcagtt	cctcgcctta	ggttgtaaag	ggagggtctta	ctacctccat	atacgaacac	5760
10	accggcgacc	caagttcctt	cgtcggtagt	cctttctacg	tgactcctag	ccaggagagc	5820
	tcttaaacct	tctgcaatgt	tctcaaattt	cgggttggaa	cctccttgac	cacgatgctt	5880
	tccaaaccac	cctccttttt	tgcgcctgcc	tccatcacc	tgaccccggt	gtccagtgt	5940
15	tgggccttct	cctgggtcat	ctgcggggcc	ctgctctatc	gctcccggtg	gcacgtcagg	6000
	ctcaccatct	gggccacctt	cttgggtggt	ttcaaaataa	tgggttccc	ctacagggtg	6060
20	gaaaaatggc	cttctacctg	gagggggcct	gcgcgggtgga	gacccggtatg	atgatgactg	6120
	actactggga	ctcctggggc	tcttttctcc	acgtccacga	cctctccccc	tggtctcttc	6180
	acgacttccc	cccctggctc	tttcacgtcc	tctaccccg	cggcctccac	tacctcctcg	6240
25	accccggcct	ccactacctc	ctcgaccccg	gcctccactg	cctcctcgac	cccggcctcc	6300
	acctcctgct	cctgcccctc	ctgctcctgc	ccctcctcct	gctcctgccc	ctcctgcccc	6360
	tctgctcct	gcccctcctg	cccctcctgc	tctgcccct	cctgcccctc	ctgctcctgc	6420
30	ccctcctgcc	cctcctcctg	ctcctgcccc	tctgcccct	cctcctgctc	ctgcccctcc	6480
	tgcccctcct	gctcctgccc	ctcctgcccc	tctgctcct	gcccctcctg	cccctcctgc	6540
35	tctgcccct	cctgctcctg	cccctcctgc	tctgcccct	cctgctcctg	cccctcctgc	6600
	ccctcctgcc	cctcctcctg	ctcctgcccc	tctgctcct	gcccctcctg	cccctcctgc	6660
	ccctcctgct	cctgcccctc	ctcctgctcc	tgcccctcct	gcccctcctg	cccctcctcc	6720
40	tgctcctgcc	cctcctgccc	ctcctcctgc	tctgcccct	cctcctgctc	ctgcccctcc	6780
	tgcccctcct	gcccctcctc	ctgctcctgc	ccctcctgcc	cctcctcctg	ctcctgcccc	6840
45	tctcctgct	cctgcccctc	ctgcccctcc	tgcccctcct	cctgctcctg	cccctcctcc	6900
	tgctcctgcc	cctcctgccc	ctcctgcccc	tctgcccct	cctcctgctc	ctgcccctcc	6960
	tctgctcct	gcccctcctg	ctcctgcccc	tcccgtcct	gctcctgctc	ctgttccacc	7020
50	gtgggtccct	ttgcagccaa	tgcaacttgg	acgtttttgg	ggtctccgga	caccatctct	7080
	atgtcttggc	cctgatcctg	agccgcccgg	ggctcctgggt	cttcgcctc	ctcgtcctcg	7140
	tctcttccc	cgtcctcgtc	catgggtatc	accccctctt	ctttgaggtc	cactgcgcgc	7200
55	ggagccttct	ggtccagatg	tgtctccctt	ctctcctagg	ccatttccag	gtcctgtacc	7260
	tggcccctcg	tcagacatga	ttcacactaa	aagagatcaa	tagacatctt	tattagacga	7320

EP 3 351 261 A1

	cgctcagtga	atacagggag	tgacagactcc	tgccccctcc	aacagccccc	ccaccctcat	7380
	ccccttcatg	gtcgctgtca	gacagatcca	ggctctgaaaa	ttccccatcc	tccgaaccat	7440
5	cctcgtcctc	atcaccaatt	actcgcagcc	cggaaaactc	ccgctgaaca	tcctcaagat	7500
	ttgcgtcctg	agcctcaagc	caggcctcaa	attcctcgtc	cccctttttg	ctggacggta	7560
	gggatgggga	ttctcgggac	ccctcctctt	cctcttcaag	gtcaccagac	agagatgcta	7620
10	ctggggcaac	ggaagaaaag	ctgggtgcgg	cctgtgagga	tcagcttatc	gatgataagc	7680
	tgtcaaacat	gagaattctt	gaagacgaaa	gggcctcgtg	atacgcctat	ttttataggt	7740
	taatgtcatg	ataataatgg	tttcttagac	gtcaggtggc	acttttcggg	gaaatgtgcg	7800
15	cggaaccctt	atttgtttat	ttttctaaat	acattcaaat	atgtatccgc	tcagagaca	7860
	ataaccctga	taaatgcttc	aataatattg	aaaaaggaag	agtatgagta	ttcaacattt	7920
	ccgtgtcgcc	cttattccct	tttttgcggc	attttgcctt	cctgtttttg	ctcaccacga	7980
20	aacgctgggtg	aaagtaaaag	atgctgaaga	tcagttgggt	gcacgagtgg	gttacatcga	8040
	actggatctc	aacagcggta	agatccttga	gagttttcgc	cccgaagaac	gttttccaat	8100
25	gatgagcact	tttaaagttc	tgctatgtgg	cgcggtatta	tcccgtgttg	acgccgggca	8160
	agagcaactc	ggtcgccgca	tacactattc	tcagaatgac	ttggttgagt	actcaccagt	8220
	cacagaaaag	catcttacgg	atggcatgac	agtaagagaa	ttatgcagtg	ctgccataac	8280
30	catgagtgat	aacactgcgg	ccaacttact	tctgacaacg	atcggaggac	cgaaggagct	8340
	aaccgctttt	ttgcacaaca	tgggggatca	tgtaactcgc	cttgatcgtt	gggaaccgga	8400
	gctgaatgaa	gccataccaa	acgacgagcg	tgacaccacg	atgcctgcag	caatggcaac	8460
35	aacgttgccg	aaactattaa	ctggcgaaact	acttactcta	gcttcccggc	aacaattaat	8520
	agactggatg	gaggcggata	aagttgcagg	accacttctg	cgctcggccc	ttccggctgg	8580
	ctggtttatt	gctgataaat	ctggagccgg	tgagcgtggg	tctcgcggta	tcattgcagc	8640
40	actggggcca	gatggtaagc	cctcccgtat	cgtagttatc	tacacgacgg	ggagtcaggc	8700
	aactatggat	gaacgaaata	gacagatcgc	tgagataggt	gcctcactga	ttaagcattg	8760
	gtaactgtca	gaccaagttt	actcatatat	acttttagatt	gatttaaaac	ttcattttta	8820
45	atttaaaagg	atctaggtga	agatcctttt	tgataatctc	atgaccaaaa	tccttaacg	8880
	tgagttttcg	ttccactgag	cgtcagaccc	cgtagaaaag	atcaaaggat	cttcttgaga	8940
	tccttttttt	ctgcgcgtaa	tctgctgctt	gcaaacaaaa	aaaccaccgc	taccagcggc	9000
50	ggtttggttg	ccggatcaag	agctaccaac	tctttttccg	aaggtaactg	gcttcagcag	9060
	agcgcagata	ccaaatactg	tccttctagt	gtagccgtag	ttaggccacc	acttcaagaa	9120
55	ctctgtagca	ccgcctacat	acctcgtctc	gctaatacctg	ttaccagtgg	ctgctgccag	9180
	tggcgataag	tcgtgtctta	ccgggttgga	ctcaagacga	tagttaccgg	ataaggcgca	9240

EP 3 351 261 A1

	gcggtcgggc tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac	9300
	cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgcttcccg aaggagagaaa	9360
5	ggcggacagg tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttcc	9420
	agggggaaac gcctggatatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg	9480
	tcgatttttg tgatgctcgt caggggggag gagcctatgg aaaaacgcca gcaacggggc	9540
10	cttttttacgg ttccctggcct tttgctggcc ttgaagctgt ccctgatggg cgtcatctac	9600
	ctgcctggac agcatggcct gcaacggggg catcccgatg ccgccggaag cgagaagaat	9660
15	cataatgggg aaggccatcc agcctcgcgt cgcgaacgcc agcaagacgt agcccagcgc	9720
	gtcggccccc agatgcgccg cgtgcggctg ctggagatgg cggacgcgat ggatatgttc	9780
	tgccaagggt tggtttgccg attcacagtt ctccgcaaga attgattggc tccaattctt	9840
20	ggagtgggtga atccgttagc gaggtgccgc cctgcttcat ccccgtaggc cgttgctcgc	9900
	gtttgctggc ggtgtccccg gaagaaatat atttgcatgt ctttagttct atgatgacac	9960
	aaaccccgcc cagcgtcttg tcattggcga attcgaacac gcagatgcag tcggggcggc	10020
25	gcggtccgag gtccacttcg catattaagg tgacgcgtgt ggcctcgaa accgagcgac	10080
	cctgcagcga cccgcttaac agcgtcaaca gcgtgccgca gatcccgagg ggcaatgaga	10140
	tatgaaaaag cctgaactca ccgcgacgtc tgtcgagaag tttctgatcg aaaagttcga	10200
30	cagcgtctcc gacctgatgc agctctcgga gggcgaagaa tctcgtgctt tcagcttcga	10260
	tgtaggaggg cgtggatatg tcctgcgggt aaatagctgc gccgatgggt tctacaaaga	10320
35	tcgttatgtt tatcggcact ttgcatcggc cgcgctcccg attccggaag tgcttgacat	10380
	tggggaattc agcgagagcc tgacctattg catctccgcg cgtgcacagg gtgtcacgtt	10440
	gcaagacctg cctgaaaccg aactgcccgc tgttctgcag ccggtcgcgg aggccatgga	10500
40	tgcgatcgct gcggccgatc ttagccagac gagcgggttc ggccattcg gaccgcaagg	10560
	aatcgggtcaa tacaactacat ggcgtgattt catatgcgcg attgctgatc cccatgtgta	10620
	tcactggcaa actgtgatgg acgacaccgt cagtgcgtcc gtgcgcagg ctctcgatga	10680
45	gctgatgctt tgggcccagg actgccccga agtccggcac ctcgtgcacg cggatttcgg	10740
	ctccaacaat gtccctgacgg acaatggccg cataacagcg gtcattgact ggagcgaggc	10800
	gatgttcggg gattcccaat acgaggctgc caacatcttc ttctggaggc cgtgggttggc	10860
50	ttgtatggag cagcagacgc gctacttcga gcggaggcat ccggagcttg caggatcgcc	10920
	gcggctccgg gcgtatatgc tccgcattgg tcttgaccaa ctctatcaga gcttggttga	10980
55	cggcaatttc gatgatgcag cttgggcgca gggtcgatgc gacgcaatcg tccgatccgg	11040
	agccgggact gtcgggcgta cacaatcgc ccgcagaagc gcggccgtct ggaccgatgg	11100

ctgtgtagaa gtactcgccg atagtggaaa ccgacgcccc agcactcgtc cggatcgggg 11160
 gatgggggag gctaactgaa acacggaagg agacaataacc ggaaggaacc cgcgctatga 11220
 5 cggcaataaa aagacagaat aaaacgcacg ggtgttgggg cgtttgttca taaacgcggg 11280
 gttcgggtccc agggctggca ctctgtcgat accccaccga gaccccatg gggccaatac 11340
 10 gcccgcggtt cttccttttc cccacccccc cccccaagtt cgggtgaagg ccaggggtc 11400
 gcagccaacg tcggggcggc agggcctgcc atagccactg gcccgtggg ttagggacgg 11460
 ggtcccccac ggggaatggt ttatggttcg tgggggttat tattttgggc gttgcgtggg 11520
 15 gtcaggtcca cgactggact gagcagacag acccatggtt tttggatggc ctgggcatgg 11580
 accgcatgta ctggcgcgac acgaacaccg ggcgtctgtg gctgccaaac acccccgacc 11640
 cccaaaaacc accgcgcgga tttctggcgt gccaaagctag tcgaccaatt ctcatgtttg 11700
 20 acagcttatc atcgcagatc cgggcaacgt tggtgccatt gctgcaggcg cagaactggt 11760
 aggtatggaa gatctataca ttgaatcaat attggcaatt agccatatta gtcattggtt 11820
 atatagcata aatcaatatt ggctattggc cattgcatac gttgtatcta tatcataata 11880
 25 tgtacattta tattggctca tgtccaatat gaccgccatg ttgacattga ttattgacta 11940
 gttattaata gtaatcaatt acgggggtcat tagttcatag cccatatatg gagttccgcg 12000
 30 ttacataact tacggtaaat ggcccgctg gctgaccgcc caacgacccc cgccattga 12060
 cgtcaataat gacgtatgtt cccatagtaa cgccaatagg gactttccat tgacgtcaat 12120
 ggggtggagta ttacggtaa actgccact tggcagtaca tcaagtgtat catatgccaa 12180
 35 gtccgcccc ctttgacgtc aatgacggta aatggccgc ctggcattat gccagtaca 12240
 tgaccttacg ggactttcct acttggcagt acatctacgt attagtcac gctattacca 12300
 tgggtgatgcg gttttggcag tacaccaatg ggcgtggata gcggtttgac tcacggggat 12360
 40 ttccaagtct ccacccatt gacgtcaatg ggagtttgtt ttggcaccaa aatcaacggg 12420
 actttccaaa atgtcgtaat aaccccgccc cgttgacgca aatgggcggg aggcgtgtac 12480
 45 ggtgggaggt ctatataagc agagctcgtt tagtgaaccg tcagatctct agaagctgg 12539

Claims

- 50 1. A combination medicament, comprising
- an IL-12 polypeptide, or a nucleic acid expression vector comprising a sequence encoding said IL-12 polypeptide, and
 - a non-agonist ligand capable of binding to one of PD-1, PD-L1 or PD-L2 with a dissociation constant of at
- 55 least 10^{-7} M^{-1} , wherein said non-agonist ligand is provided as a dosage form for systemic delivery,
- for use in the therapy of a malignant neoplastic disease, wherein

- said IL-12 polypeptide, or said nucleic acid expression vector, is provided by administration into a tumour, into the vicinity of a tumour, or to the lymph node associated with a tumour.

2. The combination medicament for use in the therapy of a malignant neoplastic disease according to claim 1, wherein said non-agonist ligand is selected from the group consisting of an antibody, an antibody fragment, and an antibody-like molecule.

3. The combination medicament for use in the therapy of a malignant neoplastic disease according to claim 1 or 2, wherein said non-agonist ligand is a gamma immunoglobulin that binds to one of PD-1, PD-L1 or PD-L2.

4. The combination medicament for use in the therapy of a malignant neoplastic disease according to any one of the preceding claims, wherein said IL-12 polypeptide comprises

- a. a polypeptide sequence at least 95% identical to the sequence of human p35 (SEQ ID 05), and
- b. a polypeptide sequence at least 95% identical to the sequence of human p40 (SEQ ID 06).

5. The combination medicament for use in the therapy of a malignant neoplastic disease according to claim 4, wherein said IL-12 polypeptide comprises an immunoglobulin G crystallisable fragment.

6. The combination medicament for use in the therapy of a malignant neoplastic disease according to claim 4 or 5, wherein said IL-12 polypeptide comprises a human immunoglobulin G subgroup 4 crystallisable fragment.

7. The combination medicament for use in the therapy of a malignant neoplastic disease according to claim 6, wherein said IL-12 polypeptide comprises

- a. an immunoglobulin G crystallisable fragment and a recombinant or synthetic human IL-12 sequence, or
- b. a sequence at least 95% identical to SEQ ID 01.

8. The combination medicament for use in the therapy of a malignant neoplastic disease according to any one of the preceding claims, wherein said IL-12 polypeptide, or said nucleic acid expression vector comprising a sequence encoding said IL-12 polypeptide, is provided as a dosage form for intratumoural injection.

9. The combination medicament for use in the therapy of a malignant neoplastic disease according to any one of the above claims, wherein said non-agonist ligand is provided as a dosage form for intravenous injection or local application.

10. The combination medicament for use in the therapy of a malignant neoplastic disease according to any one of the preceding claims, wherein said IL-12 polypeptide is provided as a dosage form for intratumoural delivery or local delivery in the vicinity of the tumour, and said non-agonist ligand is provided as a dosage form for systemic delivery.

11. A combination medicament according to at least one of claims 1 to 10 for use in a method of therapy of glioma, glioblastoma multiforme, meningioma, secondary brain cancer, brain metastases, melanoma, pancreatic cancer, lung cancer, prostate cancer or bladder cancer.

12. The combination medicament according to claim 1, wherein


- said IL-12 polypeptide is a fusion protein comprising the amino acid of human p40, the amino acid sequence of human p35 and the crystallisable fragment of human IgG4,
- said IL-12 polypeptide is provided as a dosage form for intratumoural delivery, and wherein
- said non-agonist ligand is an immunoglobulin G provided as a dosage form for systemic delivery,

for use in the treatment of malignant neoplastic disease, particularly glioma, glioblastoma multiforme, meningioma, secondary brain cancer, brain metastases, melanoma, pancreatic cancer, lung cancer, prostate cancer or bladder cancer.

13. The combination medicament for use in the therapy of a malignant neoplastic disease according to at least one of claims 1 to 10, wherein said nucleic acid expression vector is an adenovirus, an adeno-associated virus, a lentivirus or a herpesvirus.

Fig. 1

a



b




Fig. 1 c




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8



GI261 Fc d 21



GI261 Fc d 91 after
IL-12Fc/ α CTLA-4
treatment

Fig. 9



PBS/PBS vs IL-12Fc/αPD-1 $P = 0.0064$

Fig 10





Fig. 11





EUROPEAN SEARCH REPORT

Application Number
EP 18 16 0057

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	P. L. TRIOZZI: "Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma", CLINICAL CANCER RESEARCH, vol. 11, no. 11, 1 June 2005 (2005-06-01), pages 4168-4175, XP055046157, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-04-2283 * abstract * * page 4172, left-hand column, paragraph 1 *	1-13	INV. A61K38/20 A61K39/395 A61K45/06 A61P35/00
T	----- SABEL ET AL: "Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells", SURGERY, C.V. MOSBY CO., ST. LOUIS, US, vol. 142, no. 5, 2 November 2007 (2007-11-02), pages 749-760, XP022320882, ISSN: 0039-6060, DOI: 10.1016/J.SURG.2007.05.008 * page 758, right-hand column, lines 1-3, paragraph 2 * ----- -/--	1-13	TECHNICAL FIELDS SEARCHED (IPC) A61K A61P
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 24 May 2018	Examiner Zellner, Eveline
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	

 2
EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

 Application Number
EP 18 16 0057

5

10

15

20

25

30

35

40

45

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	ZHONG RUI-KUN ET AL: "Induction, selection and expansion of acute myeloid leukemia reactive autologous T cells for adoptive immunotherapy", BLOOD; 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, no. 11 part 1, 16 November 2005 (2005-11-16), pages 1-2, XP009157602, ISSN: 0006-4971 * abstract *	1-13	TECHNICAL FIELDS SEARCHED (IPC)
A	P. E. FECCI ET AL: "Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function", CLINICAL CANCER RESEARCH, vol. 13, no. 7, 1 April 2007 (2007-04-01), pages 2158-2167, XP055022031, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-2070 * the whole document *	1-13	
Y	YUNHUI LIU ET AL: "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", CANCER GENE THERAPY, vol. 9, no. 1, 1 January 2002 (2002-01-01), pages 9-15, XP055046148, ISSN: 0929-1903, DOI: 10.1038/sj.cgt.7700399 * abstract *	1-13	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 24 May 2018	Examiner Zellner, Eveline
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)

50

55



EUROPEAN SEARCH REPORT

Application Number
EP 18 16 0057

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	ASCIERTO PAOLO A ET AL: "Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies", SEMINARS IN ONCO, ELSEVIER, US, vol. 27, no. 5, 1 October 2010 (2010-10-01), pages 508-516, XP008175440, ISSN: 1532-8708, DOI: 10.1053/J.SEMINONCOL.2010.09.008 [retrieved on 2010-11-10] * page 512, column 1, paragraph 2 * -----	1-13	
Y	MANGSBO SARA M ET AL: "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 33, no. 3, 1 April 2010 (2010-04-01), pages 225-235, XP009144370, ISSN: 1524-9557 * page 234, column 1, paragraph 3 - column 2, paragraph 2 * -----	1-13	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search		Date of completion of the search	Examiner
Munich		24 May 2018	Zellner, Eveline
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 2011137289 A1 [0020]

Non-patent literature cited in the description

- **HODI et al.** *N Engl J Med*, 2010, vol. 363, 711-723 [0006]
- **GRAZIANI et al.** *Pharmacol Res*, January 2012, vol. 65 (1), 9-22 [0006]
- **CHEMICAL ABSTRACTS**, 745013-59-6 [0033]
- **CHEMICAL ABSTRACTS**, 477202-00-9 [0033]
- **SOFIETTI et al.** *J Neurol*, 2002, vol. 249, 1357-1369 [0039]
- **BELLADONNA et al.** *J Immunol*, 2002, vol. 168, 5448-5454 [0047] [0062]
- **SCHMIDT.** *Curr Opin Drug Discov Devel*, 2009, vol. 12, 284-295 [0047]
- **EISENRING et al.** *Nat Immunol*, 2010, vol. 11, 1030-1038 [0047]
- **PEGGS et al.** *J Exp Med*, 2009, vol. 206, 1717-1725 [0057] [0058]
- **TRINCHIERI.** *Nat Rev Immunol*, 2003, vol. 3, 133-146 [0067]